Prof.

BUTI SEBASTIANO

Professore di II fascia

Dipartimento di Medicina e Chirurgia (https://www.unipr.it/ugov/organizationunit/186474)

Settore scientifico disciplinare

Oncologia medica

Curriculum Vitae | **Orario di ricevimento** | **Insegnamenti** | **Incarichi** | **Ricerca**

Istruzione:

1990: Conseguita Licenza in Solfeggio e Teoria Musicale presso il Conservatorio di musica “Arrigo Boito” di Parma; presso lo stesso istituto conseguito il Settimo Anno di Corso in Violino nel 1996.

1996: Conseguito Diploma di Maturità Scientifica presso il Liceo Scientifico “Guglielmo Marconi” (Parma).

1996/1997 iscrizione al corso di Laurea in Medicina e Chirurgia presso l’Università degli Studi di Parma: a partire da ottobre 2000 a maggio 2004 frequenza nel Reparto di Clinica Medica e Nefrologia e del Day Hospital Dipartimentale (Prof. Carlo Buzio) presso la stessa Università.

12 Giugno 2003: Conseguita Laurea nel corso di Laurea Specialistica in Medicina e Chirurgia presso l’Università degli Studi di Parma. Titolo della tesi discussa: “*Carcinoma renale metastatico: indici prognostici valutati in 145 pazienti trattati con rIL-2 ed rIFN-α a basse dosi*”.

6 Novembre 2007: Conseguito Diploma di Specializzazione in Oncologia presso l’Università degli Studi di Parma con seguente votazione: 50/50 con lode. Titolo della tesi discussa: “*Combinazione di Bevacizumab, Immunoterapia a basse dosi e Chemioterapia (BIC) in pazienti affetti da tumore renale metastatico: studio di dose-finding e fase II*”.

19 Aprile 2016: Conseguito Dottorato di Ricerca (2013-2015) in “Fisiopatologia renale e malattie osteometaboliche” presso l’Università degli Studi di Parma. Titolo della tesi discussa: “V*alidation of a new easy score to predict outcome in early stage renal cell carcinoma*”.

9-11 Febbraio 2017: Master Nazionale Fondazione NIBIT di I livello in Immuno-Oncologia, Siena.

31 Ottobre 2018: Ottenimento dell’Abilitazione Scientifica Nazionale (ASN) per professore di II fascia nel settore concorsuale 06/D3 “Malattie del Sangue, Oncologia e Reumatologia”, valida fino al 31/10/2029.

Da febbraio 2021 a maggio 2021 conseguito Corso di Alta Formazione in Statistica Medica presso l’Università di Bologna.

17 Dicembre 2023: Ottenimento dell'Abilitazione Scientifica Nazionale (ASN) per professore di I fascia nel Gruppo Scientifico-Disciplinare 06/MEDS-09 "Malattie del Sangue, Oncologia e Reumatologia" (già Settore Concorsuale 06/D3) - Settore Scientifico-Disciplinare MEDS-09/A "Oncologia Medica" (già MED/06), valida fino al 17/12/2034.

A partire dal 2001 partecipazione a 263 eventi formativi nazionali ed internazionali: congressi, corsi, corsi online, conferenze, live webinars, advisory boards ed investigators' meetings [relatore/moderatore in 84 convegni/corsi].

Esperienza professionale:

- Esperienza pluristagionale come operaio agricolo, dal 1992 al 1997.
- Esperienza pluristagionale come operaio in ditta di conserve alimentari Mutti S.p.A. di Basilicanova (PR), dal 1995 al 1998.
- Collaborazione a tempo determinato (150 ore) presso l'Università degli Studi di Parma durante il IV ed il VI anno di corso di Laurea in Medicina e Chirurgia.
- Attività di supporto al tutorato (150 ore) presso l'Università degli Studi di Parma durante il V anno di corso di laurea in Medicina e Chirurgia.
- Monitor presso azienda farmaceutica (Chiron Italia S.r.l., Milano) nel 2000 e nel 2003-2004: raccolta dati relativi a due studi randomizzati multicentrici su pazienti affetti da carcinoma renale e trattati con immunoterapia adiuvante o palliativa.
- Medico frequentatore, da giugno 2003 a febbraio 2004, presso il Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione dell'Università degli Studi di Parma (Direttore Prof. Carlo Buzio); da febbraio ad aprile 2004 presso l'U.O. di Oncologia Medica dell'Azienda Ospedaliero-Universitaria di Parma (Direttore Dott. Andrea Ardizzoni).
- Sostituzione medici di base da settembre 2003 (Corniglio e Parma) a settembre 2005.
- "Medico selezionatore" presso l'AVIS Provinciale di Parma da ottobre 2003 a maggio 2004.
- Guardia Medica - servizio di continuità assistenziale presso il distretto Sud-Est dell'ASL di Parma (sedi di Palanzano, Langhirano, Neviano Arduini, Tizzano e Corniglio) a partire da febbraio 2004 a settembre 2007 per un totale di 2990 ore di servizio.
- Contratto di collaborazione a tempo determinato dall'1 settembre al 30 novembre 2007 presso l'U.O. di Medicina e Oncologia degli Istituti Ospitalieri di Cremona (Direttore Dott. Rodolfo Passalacqua).
- Contratto di assunzione a tempo determinato, in qualità di dirigente medico, a partire dall'1 dicembre 2007 al 14 febbraio 2010 presso l'U.O. di Medicina e Oncologia degli Istituti Ospitalieri di Cremona (Dott. Rodolfo Passalacqua).
- Attività di *tutor* per studenti e "tesisti" del corso di Medicina e Chirurgia dell'Università di Parma, a partire dal 2008 e a tutt'oggi in corso.
- Attività didattica e *tutor* per gli specializzandi della Scuola di Specializzazione in Oncologia e della Scuola di Specializzazione in Nefrologia dell'Università degli Studi di Parma, a partire dal 2012 e a tutt'oggi in corso.
- Contratto di assunzione a tempo indeterminato, in qualità di dirigente medico, a partire dal 15 febbraio 2010 al 15 gennaio 2012 presso l'U.O. di Oncologia degli Istituti Ospitalieri di Cremona (Direttore Dott. Rodolfo Passalacqua).
- Contratto di assunzione a tempo indeterminato, in qualità di dirigente medico, a partire dal 16 gennaio 2012 presso l'U.O. di Oncologia Medica dell'Azienda Ospedaliero-Universitaria di Parma (Direttore Dott. Andrea Ardizzoni fino a luglio 2014, Dott. Carmine Pinto da agosto 2014 ad agosto 2015, Dott. Francesco Leonardi da settembre 2015 a maggio 2023, Prof. Marcello Tiseo da maggio 2023 ad oggi), a tutt'oggi in corso.
- Attribuzione di Incarico di Case Manager Esperto presso l'U.O. di Oncologia Medica dell'Azienda Ospedaliero-Universitaria di Parma, a partire dall'1 dicembre 2012 e a tutt'oggi in corso.
- Referente oncologo per le consulenze nell'ambito del Percorso Diagnostico Terapeutico Assistenziale (PDTA) Interaziendale per la Valutazione di Idoneità del Paziente Candidato Ricevente di Trapianto Renale e del Donatore Vivente dell'Azienda Ospedaliero-Universitaria di Parma, da gennaio 2012 e a tutt'oggi in corso.
- Referente oncologo per il gruppo di studio della malattia di Erdheim-Chester dell'Azienda Ospedaliero-Universitaria di Parma, da luglio 2015 e a tutt'oggi in corso.
- Referente oncologo per l'Azienda Ospedaliero-Universitaria di Parma della "Macroarea paziente con patologia oncologica" nel contesto dell'Osservatorio Regionale per le Medicine Non Convenzionali (OMNCER), da agosto 2015 e a tutt'oggi in corso.
- Incaricato come componente, in qualità di medico referente, dell'organigramma dell'Unità di Fase I dell'Azienda Ospedaliero-Universitaria di Parma, da novembre 2017 e a tutt'oggi in corso.
- Referente oncologo per i tumori del rene e delle vie urinarie nell'ambito del Percorso Diagnostico-Terapeutico delle patologie oncologiche del distretto genitourinario dell'Azienda Ospedaliero-Universitaria di Parma, da gennaio 2019 e a tutt'oggi in corso.
- Attività di *sub-investigator* in oltre 150 studi clinici sponsorizzati ed indipendenti, sia nell'ambito della patologia polmonare che genitourinaria.
- Attività di *principal investigator* in numerosi studi clinici indipendenti ed sponsorizzati nell'ambito della patologia genitourinaria.
- Titolare e *principal investigator* di "Investigator-sponsored research" per lo studio pre-clinico intitolato "*Treatment sequence after AXitinib-based Immuno-Therapeutic combination in Renal Cell Carcinoma: searching for hints from preclinical settings (AXIT study)*" finanziato da Pfizer s.r.l. [Pfizer Tracking Number 52313943] (2020-2023).
- Attività di revisore per le seguenti riviste internazionali: *Cancer Chemotherapy & Pharmacology, Current Medical Literature – Kidney Cancer, Lancet,The Lancet Oncology, Lung Cancer' Expert Opinion on Pharmacotherapy, OncoTargets and Therapy, Cancer Treatment Reviews, BMC Cancer, Current Drug Targets, Pharmaceutics, Oncotarget, Clinical and Traslational Oncology, Targeted Oncology, Translational Cancer Research, The International Journal of Biological Markers, Frontiers in Pharmacology, Oncogenesis, Current Drug Metabolism, Transplantation Reviews,Tumori Journal, Expert Opinion on Biological Therapy, Future Oncology, British Journal of Clinical Pharmacology, Expert Review of Clinical Pharmacology, Clinical Drug Investigation, Critical Reviews in Oncology/Hematology, European Urology Oncology, BMC Medicine, Expert Review of Anticancer Therapy, British Journal of Cancer, ESMO Open, Frontiers in Oncology, Journal of Urology, Chemotherapy, Nature Reviews Urology, Cancers, Journal for ImmunoTherapy of Cancer, Clinical Genitourinary Cancer, The Oncologist, Heliyon, Scandinavian Journal of Immunology, BMJ Oncology, Translational Andrology and Urology, British Journal of Urology International, JAMA Network Open, Case Reports in Oncology*.

- Incarico di insegnamento (Professore a contratto) per la scuola di Specializzazione in Oncologia presso l'Università di Parma, dal 2020 e a tutt'oggi in corso.
- Nomina di Cultore della Materia in Oncologia (SSD 06/D3) da parte del Dipartimento di Medicina e Chirurgia dell'Università di Parma, da novembre 2020 e a tutt'oggi in corso.
- Coordinatore del gruppo "Tumori Rari" del gruppo Italian Network for Research in Urologic Oncology (MeeT-Uro), da maggio 2019 e a tutt'oggi in corso.
- Estensore linee guida AIOM (Associazione Italiana Oncologia Medica) 2020, 2021, 2022, 2023 e 2024 per il tumore del rene.
- Attività di *reviewer* di progetto di ricerca per conto dell'Austrian Science Fund (FWF), in febbraio 2021 e febbraio 2022.
- Attività di *guest editor* per lo Special Issue intitolato "*Clinical Outcomes of Advanced Cancer Patients Treated with Immune-Checkpoint Inhibitors: From the Inflamed Tumor to the Inflamed Patient*" della rivista **Cancers,** da marzo 2021 a dicembre 2021 [https://www.mdpi.com/journal/cancers/special_issues/inflamed_tumor_to_the_inflamed_patient (https://www.mdpi.com/journal/cancers/special_issues/inflamed_tumor_to_the_inflamed_patient)
- Ricercatore a contratto a tempo determinato tipo B (SC 06/D3 – SSD MED/06), presso l'Università di Parma – Dipartimento di Medicina e Chirurgia, dall' 1 dicembre 2021 al 30 novembre 2024.
- Membro del collegio docenti del dottorato "Scienze Mediche e Chirurgiche Traslazionali (ciclo XXXVIII)" presso l'Università di Parma, da maggio 2022 ad aprile 2024.
- Attività di reviewer di progetto di ricerca per conto della regione Regione Sardegna, in settembre 2023.
- Membro del collegio docenti del dottorato "Scienze Mediche e Chirurgiche Traslazionali (ciclo XL)" presso l'Università di Parma, da maggio 2024 e a tutt'oggi in corso.
- Attività di *guest editor* per la Special Collection, "*Renal Cell Carcinoma—From Genetics to Oncological and Surgical Treatments: New Insights*," della rivista **Technology in Cancer Research & Treatment**, da luglio 2024 a tutt'oggi in corso [https://journals.sagepub.com/topic/collections-tct/tct-1-renal_cell_carc... (https://journals.sagepub.com/topic/collections-tct/tct-1-renal_cell_carcinoma_from_genetics_to_oncological?journalCode=tct)].
- Membro del comitato scientifico dell'Associazione Advanced Uro-Oncology, da ottobre 2024 e a tutt'oggi in corso.
- Professore Associato (06/MEDS-09 – MEDS-09/A), presso l'Università di Parma – Dipartimento di Medicina e Chirurgia, dall' 1 dicembre 2024 e a tutt'oggi in corso.

Grants ottenuti tramite partecipazione a bandi di ricerca competitivi:

1. Ruolo di Co-Principal Investigator (P.I. Prof. Marcello Tiseo) nel progetto di ricerca dal titolo "*A multiomicsapproach to identify prognostic and predictive features of immunotherapy in solid tumors*", vincitore del "Bando 2020 - Programma ricerca finalizzata Emilia-Romagna (FIN-RER) / Progetti di ricerca Regione-Università": ammesso al finanziamento di Euro 400.000.
2. Ruolo di Co-Principal Investigator (P.I. Prof. Marcello Tiseo) nel progetto di ricerca *Theory-enhancing* dal titolo "A Multiomic Approach to Identify Prognostic and Predictive Signatures in Advanced Non-OncogeneAddicted Non-Small Cell Lung Cancer (NSCLC) receiving Immunotherapy", vincitore del "Bando Ricerca Finalizzata 2021 (fondi 2020-2021) con destinatario istituzionale in regione Emilia-Romagna": ammesso al finanziamento di Euro 450.000.
3. Ruolo di Principal Investigator del progetto dal titolo "*CHOlesterol MEtabolism and Tumor immunemicroenvironment as biomarkers of benefit from immunotherapy in patients with metastatic renal cellcarcinoma: CHOMET study*", vincitore del "Bando di Ateneo per la ricerca 2022 - Azione B", promosso dall'Università di Parma: ammesso al finanziamento di Euro 12.000.
4. Ruolo di Principal Investigator del progetto dal titolo "*LINking CHOLesterol hoMeostasis with immune-inflammatory profiles to predict immunotherapy efficacy in patients with metastatic renal cell carcinoma and non-small cell lung cancer: the LINCHOLM study*", vincitore del "Bando PRIN (Progetti di Rilevante Interesse Nazionale) 2022", promosso dal Ministero dell'Università e della Ricerca (MUR): ammesso al finanziamento di Euro 194.817.
5. Ruolo di Co-Principal Investigator (P.I. Prof. Marcello Tiseo) nel progetto di ricerca dal titolo "*Radio-immune-genomic profiling to implement the current diagnostic performance and identify prognostic signatures in small cell lung cancer (SCLC)*", vincitore del "Bando PNRR (Piano Nazionale di Ripresa e Resilienza) 2023" per la categoria "Malattie croniche non trasmissibili ad alto impatto sui sistemi sanitari e socio-sanitari": ammesso al finanziamento di Euro 1.000.000.
6. Ruolo di Principal Investigator del progetto dal titolo "*Exploring cholesterol's role in immune checkpoint inhibitor response: identification of metabolic biomarkers and mechanisms of resistance in advanced renal cell carcinoma*" vincitore del bando "Human Technopole: National Facilities for Genomics Call for Access 24-G-PILOT".

Riconoscimenti:

- Vincitore di un **2008 ASCO (American Society of Clinical Oncology) Foundation Merit Award** ricevuto al 2008 ASCO Genitourinary Symposium (14-16 febbraio 2008, San Francisco, CA, USA) per il *riconoscimento del lavoro esemplare svolto nella realizzazione dell'abstract* "*Dose-finding/phase II trial with a combination of Bevacizumab (B) plus Immunotherapy plus Chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). A GOIRC multicentre study*".
- Vincitore del **premio "Pieter De Mulder"** indetto dalla Fondazione IRCCS Policlinico San Matteo di Pavia in occasione del "Second Pavia Interational Symposium on Advanced Kidney Cancer" (26-27 Giugno 2009, Pavia, Italia), come primo autore con età inferiore ai 40 anni, per il lavoro "*Combination of Bevacizumab plus low-doses Immunotherapy plus Chemotherapy (BIC regimen) in metastatic renal cell cancer: antitumor effects and variations of T-regulatory cells (Treg) during the treatment. A multicentre study of the Italian Oncology Group for Clinical Research (GOIRC)"*.
- Vincitore del **premio per il miglior abstract del corso "Carcinoma renale – le nuove sfide nell'era delle terapie biologiche"** (26 e 27 novembre 2010, Serralunga D'Alba [CN], Italia) con presentazione orale del lavoro "*Sunitinib con schedula modificata nel trattamento del carcinoma renale metastatico in I linea*".

- Vincitore della **borsa di studio "Federico Calabresi"** in qualità di oncologo clinico primo autore con età inferiore ai 45 anni di una delle migliori pubblicazioni edite nel corso dell'anno 2011, su riviste internazionali a elevato impact factor: "*Impressive response with imatinib in a heavily pretreated patient with metastatic c-kit mutated thimic carcinoma*" [**Journal of Clinical Oncology**, Nov 20;29(33):e803-805 (2011)], assegnata durante il congresso "Grandangolo 2011: un anno di oncologia – XIII edizione" tenutosi a Genova il 15 e 16/12/2011.
- Vincitore della **borsa di studio "Federico Calabresi"** in qualità di oncologo clinico primo autore con età inferiore ai 45 anni di una delle migliori pubblicazioni edite nel corso dell'anno 2014, su riviste internazionali a elevato impact factor: "*BOLERO-3 results: pharmacological activity or pharmacokinetic effect*? (http://www.ncbi.nlm.nih.gov/pubmed/24988929)" [**The Lancet Oncology**, Jul;15(8):e304 (2014)], assegnata durante il congresso "Grandangolo 2014: un anno di oncologia – XVI edizione" tenutosi a Genova il 01 e 02/12/2014.
- Vincitore del premio **AccMed Digital Awards – Participants** (3° posto), assegnato durante il convegno "L'Insolito Grandangolo in Oncologia – Virtual Edition 2020".
- Vincitore del premio **AIOM-Merck 2023**, promosso dall'Associazione Italiana di Oncologia Medica (AIOM) e rivolto ai migliori progetti orientati a *Soluzioni clinico assistenziali volte alla gestione multidisciplinare dei pazienti con Tumori Uroteliali*. Il premio, sostenuto da un grant incondizionato dell'Azienda Merck è stato vinto con il progetto "*Avelumab maintenance plus radiotherapy for metastatic urothelial carcinoma: a randomized multicentric phase II study*" ed è stato consegnato durante il "XXV Congresso Nazionale AIOM" tenutosi a Roma dal 10 al 12 novembre 2023.

Appartenenza a società scientifiche:

- Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC, https://www.goirc.org/ (https://www.goirc.org/)).
- Italian Network for Research in Urologic Oncology (MeeT-Uro, https://www.meet-uro.it/ (https://www.meet-uro.it/)): coordinatore del gruppo "Tumori Rari".
- Italian Innovators in Multidisciplinary & Genito-Urinary Oncology (ImGO): membro del comitato scientifico.
- Associazione Italiana Oncologia Medica (AIOM, https://www.aiom.it/ (https://www.aiom.it/)): estensore linee guida per i tumori del rene.
- Associazione Advanced Uro-Oncology: membro del comitato scientifico.
- Uro-Oncology Global Data Network (ARON project, https://aronwg.com/ (https://aronwg.com/)).

Pubblicazioni [H-index 42, numero citazioni 6375 (Google Scholar); H-index 38, numero citazioni 4825 (SCOPUS); https://topresearcherslist.com/Home/Profile/936040 (https://topresearcherslist.com/Home/Profile/936040)]

A. Abstracts, Posters e Comunicazioni orali:

1. *Long-term clinical results with low-dose Interleukin-2 and Interferon-α in 145 patients with metastatic renal cell carcinoma*. Abstract SP181 (poster vincitore del Travel Grant come uno dei migliori abstract inviati da giovani autori), XLI Congress of European Renal Association-European Dialysis and Transplant Association [ERA-EDTA], May 15-18 2004, Lisbon, Portugal.
2. *Phase III, randomised, multicentre, controlled trial of maintenance biotherapy for metastatic renal cell cancer with Interleukin-2 and Interferon-alpha-2a. A study of the Italian Oncological Group for Clinical Research (GOIRC)*. Abstract No. L33, **Annals of Oncology** 2004 Sept;l5:ii98,Supplement 2: 6th National Congress of Medical Oncology, 21-24 September, 2004: Associazione Italiana Oncologia Medica (AIOM), Bologna, Italy.
3. *Maintenance biotherapy for metastatic renal cell cancer with IL-2 and IFN-α: a phase III, randomised, multicentre trial*. Abstract No. 417O (oral communication), **Annals of Oncology** 2004 Oct;15:iii111-iii112,Supplement 4: 29th European Society for Medical Oncology (ESMO) Congress, 29 October - 2 November 2004,Vienna, Austria.
4. *Diabete e neoplasie in una coorte di soggetti diabetici ospedalizzati*. Abstract (poster), XV Congresso Nazionale dell'Associazione Medici Diabetologi (AMD); 18-21 Maggio 2005, Magazzini del Cotone, Genova, Italia.
5. *Phase III, randomised, multicentre trial of maintenance biotherapy with Interleukin-2 (IL-2) and Interferon-alpha (IFN) for metastatic renal cell cancer (RCC). A study of the Italian Oncological Group for Clinical Research (GOIRC)*. Abstract No. 4605 (poster), **Journal of Clinical Oncology** 2005 Jun;23,No 16S, Part I of II:404s,Supplement: 2005 American Society of Clinical Oncology (ASCO) 41th Annual Meeting; May 13-17, 2005; Orange County Convention Center; Orlando, Florida, USA.
6. *La terapia adiuvante del carcinoma renale: stato dell'arte*. Abstract (oral communication), Convegno "Aspetti Biologici e Terapia del Carcinoma Renale: Stato dell'Arte e Prospettive Future"; Polo Didattico e di Ricerca di Crema, 17-18 Giugno 2005.
7. *Phase III, randomized, multicentre trial of maintenance of biotherapy with Interleukin-2 (IL-2) and Interferon-alpha (IFN) for metastatic renal cell cancer (RCC)*. Abstract (oral communication selezionata), Convegno "Aspetti Biologici e Terapia del Carcinoma Renale: Stato dell'Arte e Prospettive Future"; Polo Didattico e di Ricerca di Crema, 17-18 Giugno 2005.
8. *Gefitinib plus interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)*. Abstract No. B8, **Annals of Oncology** 2005 Oct;l6:vii21,Supplement 7: 7th National Congress of Medical Oncology, 18-21 October, 2005: Associazione Italiana Oncologia Medica (AIOM), Napoli, Italy.
9. *Phase II study of Chemotherapy with Oxaliplatin (ox), Irinotecan (ir), Levo-folinic acid (L-FA) and 5-Fluorouracil (5-FU) (COFFI) in metastatic gastric cancer (MGC)*. Abstract No. E14, **Annals of Oncology** 2005 Oct;l6:vii52,Supplement 7: 7th National Congress of Medical Oncology, 18-21 October, 2005: Associazione Italiana Oncologia Medica (AIOM), Napoli, Italy.

10. *Sopravvivenza e risposta alla terapia in 139 pazienti affetti da Carcinoma Renale Metastatico (CRm) trattati con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) a basse dosi. Influenza del rischio prognostico rilevato alla diagnosi*. Abstract No. C55 (oral communication), **Giornale Italiano di Nefrologia**, 2006 Marzo-Aprile;23:S18,S-35: 47° congresso nazionale della Società Italiana di Nefrologia (SIN), 24-27 Maggio 2006, Roma, Italia.
11. *Terapia di mantenimento con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) nel Carcinoma Renale Metastatico (CRm). Trial multicentrico, prospettico, randomizzato di fase III*. Abstract No. P23 (poster), **Giornale Italiano di Nefrologia**, 2006 Marzo-Aprile;23:S34,S-35: 47° congresso nazionale della Società Italiana di Nefrologia (SIN), 24-27 Maggio 2006, Roma, Italia.
12. *Dose-dense chemotherapy with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): a feasibility study*. Abstract No. 14117, **Journal of Clinical Oncology** 2006 Jun;24,No 18S, Part I of II:633s,Supplement: 2006 American Society of Clinical Oncology (ASCO) 42th Annual Meeting; June 2-6, 2006; Georgia World Congress Center; Atlanta, GA, USA.
13. *Survival and response to therapy in 139 patients with advanced renal cell carcinoma treated with low-dose IL-2 and IFN-α: influence of the prognostic risk at the time of diagnosis*. Abstract No MP218, **Nephrology Dialysis Transplantation**, 2006 July;21:Clinical Nephrology 3,Supplement 4: XLIII congress of European Renal Association-European Dialysis and Transplant Association [ERA-EDTA], July 15-18 2006, Glasgow, UK.
14. *Impact of Low-Dose of Immunotherapy (LDI) with Interleukin-2 (IL-2) and Interferon-alpha (IFNα) in Metastatic Renal Cell Cancer (mRCC) patients with different prognostic risk*. Abstract (poster) No. L3, **Annals of Oncology** 2006 Nov;l7:xi75,Supplement 11: 8th National Congress of Medical Oncology, 18-21 November, 2006: Associazione Italiana Oncologia Medica (AIOM), Milano, Italy.
15. *Role of chemotherapy in Metastatic Renal Cell Cancer (mRCC) resistant to treatment with IL-2 and IFN alpha*. Abstract No. L24, **Annals of Oncology** 2006 Nov;l7:xi80,Supplement 11: 8th National Congress of Medical Oncology, 18-21 November, 2006: Associazione Italiana Oncologia Medica (AIOM), Milano, Italy.
16. *Dose-dense chemotherapy with Docetaxel, Cisplatin, Folinic Acid and 5-Fluorouracil (TCAFF DD) in metastatic gastric cancer (MGC): feasibility study*. Abstract No. E20, **Annals of Oncology** 2006 Nov;l7:xi53,Supplement 11: 8th National Congress of Medical Oncology, 18-21 November, 2006: Associazione Italiana Oncologia Medica (AIOM), Milano, Italy.
17. *Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial*. Abstract (poster) No. P403, **Annals of Oncology** 2007 Jun;l8:iv40,Supplement 4: 5th International Symposium on Target Anticancer Therapies (TAT 2007), 8-10 March 2007, Amsterdam, The Nederlands.
18. *Combination of Bevacizumab (B) plus Immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α), plus Chemotherapy, (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial*. Abstract No. 15586, **Journal of Clinical Oncology** 2007 Jun;25,No 18S, Part I of II:656s,Supplement: 2007 American Society of Clinical Oncology (ASCO) 43th Annual Meeting; May 1-5, 2007; McCormick Place; Chicago, Illinois, USA.
19. *Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): a phase II study*. Abstract No. 15068, **Journal of Clinical Oncology** 2007 Jun;25, No 18S, Part I of II:639s,Supplement: 2007 American Society of Clinical Oncology (ASCO) 43th Annual Meeting; May 1-5, 2007; McCormick Place; Chicago, Illinois, USA.
20. *Adjuvant low-dose Interleukin-2 (IL-2) plus Interferone-alpha (IFN-alpha) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)*. Abstract (oral communication) No. LBA5028, **Journal of Clinical Oncology** 2007 Jun;25,No 18S, Part I of II:242s,Supplement: 2007 American Society of Clinical Oncology (ASCO) 43th Annual Meeting; May 1-5, 2007; McCormick Place; Chicago, Illinois, USA.
21. *Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)*. Abstract No. 18042, **Journal of Clinical Oncology** 2007 Jun;25,No 18S, Part I of II:687s,Supplement: 2007 American Society of Clinical Oncology (ASCO) 43th Annual Meeting; May 1-5, 2007; McCormick Place; Chicago, Illinois, USA.
22. *Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): a phase II study*. Abstract No. A6, **Annals of Oncology** 2007 Oct;l8:xi4,Supplement 11: 9th National Congress of Medical Oncology, 12-15 October, 2007: Associazione Italiana Oncologia Medica (AIOM), Palermo, Italy.
23. *Gefitinib plus Interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)*. Abstract No. B28, **Annals of Oncology** 2007 Oct;l8:xi30,Supplement 11: 9th National Congress of Medical Oncology, 12-15 October, 2007: Associazione Italiana Oncologia Medica (AIOM), Palermo, Italy.
24. *Overexpression of p53 protein predicts complete response to chemoradiation therapy in T2-T4 bladder cancer: ten years follow-up*. Abstract No. D15, **Annals of Oncology** 2007 Oct;l8:xi59,Supplement 11: 9th National Congress of Medical Oncology, 12-15 October, 2007: Associazione Italiana Oncologia Medica (AIOM), Palermo, Italy.
25. *Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial*. Abstract (oral communication) No. D115, **Annals of Oncology** 2007 Oct;18:xi30,Supplement 11: 9th National Congress of Medical Oncology, 12-15 October, 2007: Associazione Italiana Oncologia Medica (AIOM), Palermo, Italy.
26. *Adjuvant low-dose Interleukin-2 (IL-2) plus Interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)*. Abstract (oral communication) No. D118, **Annals of Oncology** 2007 Oct;18:xi82,Supplement 11: 9th National Congress of Medical Oncology, 12-15 October, 2007: Associazione Italiana Oncologia Medica (AIOM), Palermo, Italy.
27. *Dose-finding/phase II trial with a combination of Bevacizumab (B) plus Immunotherapy plus Chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). A GOIRC multicentre study*. Abstract ID 354 (Temp. Abst. 20245, poster) vincitore di un 2008 ASCO Foundation Merit Award: 2008 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 14-16, 2008; San Francisco, CA, USA.
28. *Chronically administered immunotherapy with low-dose IL2 and IFNα in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile*. Abstract MP169 (poster), XLV Congress of European Renal Association-European Dialysis and Transplant Association [ERA-EDTA], May 10-13, 2008 Stockholm, Sweden.
29. *Adjuvant low-dose IL2 plus IFNα in operable renal cell carcinoma: a phase III, randomized, multicenter trial*. Abstract MP174 (poster), XLV Congress of European Renal Association-European Dialysis and Transplant Association [ERA-EDTA], May 10-13, 2008 Stockholm, Sweden.
30. *Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib)*. Abstract (oral communication) No. C-07/14, **La Radiologia Medica** 2008 Maggio; Vol.113,226, Supplemento: 43° Congresso Nazionale della Società Italiana di Radiologia Medica (SIRM), 23-27 Maggio 2008, Roma, Italia.

31. *High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC)*. Abstract (poster) No. 4570, **Journal of Clinical Oncology** 2008 May;26,No 15S, Part I of II:230s,Supplement: 2008 American Society of Clinical Oncology (ASCO) 44th Annual Meeting; May 30-June 3, 2008; McCormick Place; Chicago, Illinois, USA.
32. *Bevacizumab (B) plus low-doses immunotherapy (IT), plus chemotherapy (CT) (BIC), in metastatic renal cell cancer (mRCC): antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)*. Abstract (poster) No. 5121, **Journal of Clinical Oncology** 2008 May;26,No 15S, Part I of II:279s,Supplement: 2008 American Society of Clinical Oncology (ASCO) 44th Annual Meeting; May 30-June 3, 2008; McCormick Place; Chicago, Illinois, USA.
33. *Bevacizumab (B) plus low-doses immunotherapy (IT), plus chemotherapy (CT) (BIC), in metastatic renal cell cancer (mRCC): antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)*. Abstract (oral communication) No. E4, **Annals of Oncology** 2008 Oct;19:ix44-45,Supplement 9: 10th National Congress of Medical Oncology, 11-14 October, 2008: Associazione Italiana Oncologia Medica (AIOM), Verona, Italy.
34. High efficacy of sequential chemotherapy (CT) with dose-dense modified TCF regimen (TCF-DD) followed by CT with Oxaliplatin, Folinic Acid (FA), 5-Fluorouracil (5-FU) and Irinotecan (COFFI) in metastatic gastric cancer (MGC). Abstract (oral communication) No. G3, **Annals of Oncology** 2008 Oct;19:ix63,Supplement 9: 10th National Congress of Medical Oncology, 11-14 October, 2008: Associazione Italiana Oncologia Medica (AIOM), Verona, Italy.
35. Combination of Bevacizumab plus low-doses Immunotherapy plus Chemotherapy (BIC regimen) in metastatic renal cell cancer: antitumor effects and variations of T-regulatory cells (Treg) during the treatment. A multicentre study of the Italian Oncology Group for Clinical Research (GOIRC). Abstract (oral communication) vincitore del premio "Pieter De Mulder**",** Supplement to **Oncology Reviews**: Second Pavia International Symposium on Advanced Kidney Cancer, 26-27 June 2009, Pavia, Italy.
36. *Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets*. Abstract (oral communication) No. F4, **Annals of Oncology** 2009 Oct;20:viii80,Supplement 8: 11th National Congress of Medical Oncology, 10-13 October, 2009: Associazione Italiana Oncologia Medica (AIOM), Milano, Italy.
37. *Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers*. Abstract (oral communication) No. F5, **Annals of Oncology** 2009 Oct;20:viii80,Supplement 8: 11th National Congress of Medical Oncology, 10-13 October, 2009: Associazione Italiana Oncologia Medica (AIOM), Milano, Italy.
38. *Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.* Abstract (poster) No. 4142, **Journal of Clinical Oncology** 2010 May;20,No 15S, Part I of II:336s,Supplement: 2010 American Society of Clinical Oncology (ASCO) 46th Annual Meeting; June 4-8, 2010; McCormick Place; Chicago, Illinois, USA.
39. *Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG).* Abstract (poster) No. 4615, **Journal of Clinical Oncology** 2010 May;20,No 15S, Part I of II:336s,Supplement: 2010 American Society of Clinical Oncology (ASCO) 46th Annual Meeting; June 4-8, 2010; McCormick Place; Chicago, Illinois, USA.
40. *Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study.* Abstract (poster) No. 912P, **Annals of Oncology** 2010 Oct;21:viii285,Supplement 8: 35th European Society for Medical Oncology (ESMO) Congress, 8-12 October, 2010, Milan, Italy.
41. *Feasibility of two sequential dose-dense regimens with cisplatin-gemcitabine-paclitaxel (CGP) and HD-MVAC in patients with metastatic transitional cell carcinoma of the bladder*. Abstract (poster) No. E10, **Tumori** 2010 Oct;10:S89-S90,Supplement: XII National Congress of Medical Oncology, 6-8 November, 2010: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
42. *Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): update of a phase II study*. Abstract No. H17, **Tumori** 2010 Oct;10:S145-S146,Supplement: XII National Congress of Medical Oncology, 6-8 November, 2010: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
43. *Molecular analysis of the prevalence and significance of c-kit mutations in CD117-positive thymic carcinomas (type C*). Abstract (oral communication) No. O1.3, Program and Abstracts Book: 15; 2011 International Thymic Malignancy Interest Group (ITMIG) annual meeting, 7-8 July, 2011, Amsterdam, The Netherlands.
44. *Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials.* Abstract (oral communication) No. O32.02, **Journal of Thoracic Oncology** 2011 July;6:S415: 14th World Conference on Lung Cancer (WCLC), 3-7 July, 2011, Amsterdam, The Netherlands.
45. *Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials***.** Abstract (oral communication) No. D06, **Tumori** 2011 Oct;11(2):S58,Supplement, XIII National Congress of Medical Oncology, 5-7 November, 2011: Associazione Italiana Oncologia Medica (AIOM), Bologna, Italy.
46. *A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): a pilot study.* Abstract (poster) No. 471, **Journal of Clinical Oncology** 2012;30,Supplement 5: 2012 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 2-4, 2012; San Francisco, CA, USA.
47. *Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial.* Abstract (poster) No. 220, **Journal of Clinical Oncology** 2012;30,Supplement 5: 2012 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 2-4, 2012; San Francisco, CA, USA.
48. *Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial*. Abstract No. e15160, **Journal of Clinical Oncology** 2012;30,Supplement 15: 2012 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1-5, 2012; Chicago, Illinois, USA.
49. *Erythrocyte mean corpuscular volume change during pemetrexed treatment in advanced non small cell lung cancer patients.* Abstract No. 1355, **Annals of Oncology** 2012 Sept;23:ix442,Supplement 9: 37th European Society for Medical Oncology (ESMO) Congress, 28 September - 2 October 2012,Vienna, Austria.

50. *Erythrocyte mean corpuscolar volume change during pemetrexed chemotherapy in advanced non small cell lung cancer patients.* Abstract No. D41, **Tumori** 2012 Oct;13(3):S93,Supplement, XIV National Congress of Medical Oncology, 27-29 October, 2012: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
51. *Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)*. Abstract (poster) No. P118, **European Urology Supplements** 2012 Nov;11(5):231-232, 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) Embracing Excellence in Treatment of Prostate, Bladder and Kidney Cancer, 16-18 November, 2012, Barcelona, Spain.
52. *Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial*. Abstract (poster) No. 90, **Journal of Clinical Oncology** 2013;31,Supplement 6: 2013 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 14-16, 2013; Orlando, FL, USA.
53. *Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials*. Abstract (poster) No. 208, **Journal of Clinical Oncology** 2013;31,Supplement 6: 2013 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 14-16, 2013; Orlando, FL, USA.
54. *Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD)*. Abstract No. G11, **Tumori** 2013 Oct;14(1):S74-S75,Supplement, XV National Congress of Medical Oncology, 11-13 October, 2013: Associazione Italiana Oncologia Medica (AIOM), Milano, Italy.
55. Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery? Abstract No. e15563, **Journal of Clinical Oncology** 2014;32,Supplement: 2014 American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30-June 3, 2014; McCormick Place; Chicago, Illinois, USA.
56. *Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndRoma (AWS): A preliminary report*. Abstract No. e16058, **Journal of Clinical Oncology** 2014;32,Supplement: 2014 American Society of Clinical Oncology (ASCO) 50th Annual Meeting; May 30-June 3, 2014; McCormick Place; Chicago, Illinois, USA.
57. *Renal metastases to pancreas: do not operate all and always?* Abstract (poster) No. 827P, **Annals of Oncology** 2014 Sept;25:iv287-iv287,Supplement 4: 39th European Society for Medical Oncology (ESMO) Congress, 26-30 September, 2014, Madrid, Spain.
58. *Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report*. Abstract (poster) No. H16, **Tumori** 2014 Oct;15(1):S128,Supplement, XVI National Congress of Medical Oncology, 24-26 October, 2014: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
59. *Natural history of renal metastases to the pancreas: do not operate all and always?* Abstract (poster) No. H23, **Tumori** 2014 Oct;15(1):S131,Supplement, XVI National Congress of Medical Oncology, 24-26 October, 2014: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
60. *Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)*. Abstract No. e15594, **Journal of Clinical Oncology** 2015;33,Supplement: 2015 American Society of Clinical Oncology (ASCO) 51th Annual Meeting; May 29-June 2, 2015; McCormick Place; Chicago, Illinois, USA.
61. *Relationship between enzalutamide activity and previous antiandrogen withdrawal syndrome (AWS) in patients with metastatic castration-resistant prostate cancer (MCRPC)*. Abstract No. 167, **Anticancer Research** 2015;6(35):3726-3727, 25th Annual Meeting Of The Italian Society of Uro-Oncology (SIUrO); June 21-23, 2015, Roma, Italy.
62. *Primo caso di carcinoma vescicale sarcomatoide associato a BKV in paziente trapiantato di rene: possibile ruolo dell'immunoistochimica per BKV-TAg e p16 su citologia urinaria nella diagnosi precoce di neoplasia.* Abstract (poster) No. 336POA, **Giornale Italiano di Nefrologia** 2015;32(S65):130, 56° Congresso Nazionale della Società Italiana di Nefrologia (SIN), 1-4 October, 2015: Rimini, Italy.
63. *Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)*. Abstract No. 2603, **European Journal of Cancer** 2015; 51:S512-S513),Supplement, 7th Annual Asian Oncology Summit and 11th Annual Conference of the Organization for Oncology and Translational Research, 10-12 April, 2015, Shanghai, China.
64. *Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)*. Abstract No. F14, **Annals of Oncology** 2015 Oct;26:iv287-vi57,Supplement 6: 17th National Congress of Medical Oncology, 23-25 October, 2015: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
65. *First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study*. Abstract No. e16081, **Journal of Clinical Oncology** 2016;34,Supplement: 2016 American Society of Clinical Oncology (ASCO) 52th Annual Meeting; June 4-6, 2016; McCormick Place; Chicago, Illinois, USA.
66. *TARIBO trial: Targeted therapy with or without nephrectomy in metastatic renal cell carcinoma (mRCC) - Liquid biopsy for biomarkers discovery*. Abstract (poster) No. TPS4584, **Journal of Clinical Oncology** 2016;34,Supplement: 2016 American Society of Clinical Oncology (ASCO) 52th Annual Meeting; June 4-6, 2016; McCormick Place; Chicago, Illinois, USA.
67. *First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study*. Abstract (poster) No. 832P, **Annals of Oncology** 2016 Oct;27:viii288,Supplement 6: 41th European Society for Medical Oncology (ESMO) Congress, 7-11 October, 2016, Copenhagen, Denmark.
68. *First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study*. Abstract (poster) No. C10, **Annals of Oncology** 2016 Sep;27:iv32,Supplement 4: 18th National Congress of Medical Oncology, 28-30 October, 2016: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
69. *LOH as "the missing instability" potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer*. Abstract (poster) No. 39P, **Annals of Oncology** 2016 Nov;27:viii12,Supplement 8: 4th European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology, 4-6 November, 2016, Lausanne, Switzerland.
70. *LOH as "the missing instability" potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer.* Abstract (oral communication) No. O1, **Journal of Translational Medicine** 2017;15:2,Supplement 1:O1: Immunotherapy Bridge 2016, November 30, 2016, Napoli, Italy.
71. *Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis*. Abstract (poster) No. 2175, **European Journal of Cancer** 2017 Feb;72:S190,Supplement 1: 2017 European CanCer Organisation (ECCO) - European Cancer Congress; January 27-30, 2017; Amsterdam, Holland.

72. *Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors*. Abstract (poster) No. 494, **Journal of Clinical Oncology** 2017;35,Supplement 6S: 2017 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 16-18, 2017; Orlando, FL, USA.
73. *Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors.* Abstract (poster) No. 50, **Journal of Clinical Oncology** 2017;35,Supplement 7S: 2017 American Society of Clinical Oncology (ASCO)-SITC Clinical Immuno-Oncology Symposium; February 23-25, 2017; Orlando, FL, USA.
74. *Outcome of patients with progressing oligometastatic renal cell carcinoma treated with locoregional therapy: a multicenter retrospective analysis*. Abstract No. 108, **Anticancer Research** 2017;4(37):2117-2118, 27th Annual Meeting Of The Italian Society of Uro-Oncology (SIUrO); April 20-22, 2017, Napoli, Italy.
75. *Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab*. Abstract (poster) No. 30PD_PR, **Annals of Oncology** 2017 Apr;28:ii9,Supplement 2: 7h European Lung Cancer Conference (ELCC), 5-8 May 2017, Geneva, Switzerland.
76. *Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP)*. Abstract (poster) No. 4577, **Journal of Clinical Oncology** 2017;35,Supplement: 2017 American Society of Clinical Oncology (ASCO) 53th Annual Meeting; June 2-6, 2017; McCormick Place; Chicago, Illinois, USA.
77. *The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study*. Abstract No. e16063, **Journal of Clinical Oncology** 2017;35,Supplement: 2017 American Society of Clinical Oncology (ASCO) 53th Annual Meeting; June 2-6, 2017; McCormick Place; Chicago, Illinois, USA.
78. *Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab*. Abstract No. e14514, **Journal of Clinical Oncology** 2017;35,Supplement: 2017 American Society of Clinical Oncology (ASCO) 53th Annual Meeting; June 2-6, 2017; McCormick Place; Chicago, Illinois, USA.
79. *TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents*. Abstract (poster) No. TPS4601, **Journal of Clinical Oncology** 2017;35,Supplement: 2017 American Society of Clinical Oncology (ASCO) 53th Annual Meeting; June 2-6, 2017; McCormick Place; Chicago, Illinois, USA.
80. *Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)*. Abstract (poster) No. 887P, **Annals of Oncology** 2017 Oct;28:314,Supplement 5: 42th European Society for Medical Oncology (ESMO) Congress, 8-12 September, 2017, Madrid, Spain.
81. *Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)*. Abstract (poster) No. 901P, **Annals of Oncology** 2017 Oct;28:319-320,Supplement 5: 42th European Society for Medical Oncology (ESMO) Congress, 8-12 September, 2017, Madrid, Spain.
82. *Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)*. Abstract (poster) No. 904P, **Annals of Oncology** 2017 Oct;28:320-321,Supplement 5: 42th European Society for Medical Oncology (ESMO) Congress, 8-12 September, 2017, Madrid, Spain.
83. *CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure*. Abstract (poster) No. 905P, **Annals of Oncology** 2017 Oct;28:321,Supplement 5: 42th European Society for Medical Oncology (ESMO) Congress, 8-12 September, 2017, Madrid, Spain.
84. *Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab*. Abstract (poster) No. 1643P, **Annals of Oncology** 2017 Oct;28:578,Supplement 5: 42th European Society for Medical Oncology (ESMO) Congress, 8-12 September, 2017, Madrid, Spain.
85. *Influenza Vaccine Indication During anticancer therapy with Immune-checkpoint inhibitors: A transversal challenge for patient's counselling – preliminary analysis of the retrospective, multicenter, INVIDIa study*. Abstract (poster), Cancer Bio-Immunotherapy in SIENA the XV NIBIT MEETING, 5-7 October, 2017, Siena, Italy.
86. *CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure*. Abstract (poster e presentazione orale) No. B1, **Annals of Oncology** 2017 Oct;28:17,Supplement 6: 19th National Congress of Medical Oncology, 27-29 October, 2017: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
87. *Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab*. Abstract (poster) No. E20, **Annals of Oncology** 2017 Oct;28:vi60,Supplement 6: 19th National Congress of Medical Oncology, 27-29 October, 2017: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
88. *Real world data from the Italian expanded access program (EAP): updated safety and efficacy results of nivolumab for metastatic renal cell carcinoma (mRCC)*. Late breaking abstract (presentazione orale) No. B*LBA2454, **Late Breaking Abstract Book** 2017 Oct:2-3: 19th National Congress of Medical Oncology, 27-29 October, 2017: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
89. *Retrospective analysis of patients undergoing stereotactic body radiotherapy (SBRT) in secondary non-bone lesions of metastatic renal cell carcinoma (mRCC) in treatment with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors*. Abstract (poster) No. P188, LIBRO DEGLI ABSTRACTS – Congress Proceedings, XXVI Congresso AIRO 2017:187-188, Congresso Nazionale Associazione Italiana Radioterapia Oncologica, 11-13 November, 2017, Rimini, Italy.
90. *Influenza vaccine indication during anticancer therapy with immunecheckpoint inhibithors: a transversal challenge for patient's counselling – preliminary analysis*. Abstract (poster) No. 58P, **Annals of Oncology** 2017 Dec;28:xi17,Supplement 11: European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, 7-10 December, 2017, Geneva, Switzerland.
91. *Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab*. Abstract (presentazione orale) No. 10, **Journal of Thoracic Oncology** 2018 Oct;13(4):S1-S139,Supplement: 8th European Lung Cancer Congress, 11-14 April, 2018: European Society for Medical Oncology (ESMO) e International Association for the Study of Lung Cancer (IASLC), Geneva, Switzerland.
92. *Predictive and prognostic value of clinical and molecular features in patients undergoing pulmonary metastasectomy from renal cell carcinoma***.** Abstract (poster) No. 897, 26th European Conference on General Thoracic Surgery, 27-30 May 2018: European Society of Thoracic Surgeons (ESTS) Annual Meeting, Ljubljana, Slovenia.
93. *NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC)*. Abstract (poster) No. TPS4602, **Journal of Clinical Oncology** 2018;36,Supplement: 2018 American Society of Clinical Oncology (ASCO) 54th Annual Meeting; June 1-5, 2018; McCormick Place; Chicago, Illinois, USA.

94. *Are adverse events (AEs) predictive of nivolumab activity? Data from the Italian expanded access program in metastatic renal cell carcinoma (mRCC)*. Abstract (poster) No. 885P, **Annals of Oncology** 2018 Oct;29:viii314,Supplement 8: 43th European Society for Medical Oncology (ESMO) Congress, 19-23 October, 2018, Munich, Germany.
95. *Correlation between immune-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study*. Abstract (poster) No. 891P, **Annals of Oncology** 2018 Oct;29:viii316,Supplement 8: 43th European Society for Medical Oncology (ESMO) Congress, 19-23 October, 2018, Munich, Germany.
96. *Preliminary efficacy and safety results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial: an Italian real-life experience*. Abstract (poster e presentazione orale) No. D05, **Tumori Journal** 2018 Nov;104:87-88,Supplement 4: 20th National Congress of Medical Oncology, 16-18 November, 2018: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
97. *Analysis of PD-L1 and CTLA-4 single nucleotide polymorphisms: correlations between genotype and outcome in advanced NSCLC patients treated with nivolumab*. Abstract (poster) No. D10, **Tumori Journal** 2018 Nov;104:91-92,Supplement 4: 20th National Congress of Medical Oncology, 16-18 November, 2018: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
98. *Are adverse events (AEs) predictive of Nivolumab activity? Data from the Italian Expanded Access Program in metastatic renal cell carcinoma (mRCC*). Abstract (poster) No. G02, **Tumori Journal** 2018 Nov;104:123-124,Supplement 4: 20th National Congress of Medical Oncology, 16-18 November, 2018: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
99. *IRAENE trial: a retrospective study of correlation between Immuno-Related Adverse Events (IRAEs) occurrence and disease control rate in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab*. Abstract (poster) No. G10, **Tumori Journal** 2018 Nov;104:128-129,Supplement 4: 20th National Congress of Medical Oncology, 16-18 November, 2018: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
100. *Tyrosine kinase inhibitors in renal cell carcinoma with brain metastases: cabozantinib is a safe and effective option in a real world population*. Abstract (poster) No. G13, **Tumori Journal** 2018 Nov;104:130,Supplement 4: 20th National Congress of Medical Oncology, 16-18 November, 2018: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
101. *PAzopanib as first line in MEtastatic RCC patients: A "real-world" ITalian experience (PAMERIT study) - Preliminary results.* Abstract (poster) No. 611, **Journal of Clinical Oncology** 2019;37,Supplement 7S: 2019 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 14-16, 2019; San Francisco, CA, USA.
102. *Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study*. Abstract (poster) No. 2559, **Journal of Clinical Oncology** 2019;37,Supplement: 2019 American Society of Clinical Oncology (ASCO) 55th Annual Meeting; May 31-June 4, 2019; McCormick Place; Chicago, Illinois, USA.
103. *Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study*. Abstract No. e16013, **Journal of Clinical Oncology** 2019;37,Supplement: 2019 American Society of Clinical Oncology (ASCO) 55th Annual Meeting; May 31-June 4, 2019; McCormick Place; Chicago, Illinois, USA.
104. *Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab*. Abstract No. e16077, **Journal of Clinical Oncology** 2019;37,Supplement: 2019 American Society of Clinical Oncology (ASCO) 55th Annual Meeting; May 31-June 4, 2019; McCormick Place; Chicago, Illinois, USA.
105. *Effect of gender on the outcome of patients receiving nivolumab for metastatic renal cancer: Results from a large study population*. Abstract No. e16087, **Journal of Clinical Oncology** 2019;37,Supplement: 2019 American Society of Clinical Oncology (ASCO) 55th Annual Meeting; May 31-June 4, 2019; McCormick Place; Chicago, Illinois, USA.
106. *Definitive data of TOGETHER study treatment outcome of metastatic lesions from renal cell carcinoma undergoing extra-cranial stereotactic body radiotherapy.* Abstract (presentazione orale) No. CO056, LIBRO DEGLI ABSTRACTS – Congress Proceedings, XXIX Congresso AIRO 2019:80-81, Congresso Nazionale Associazione Italiana Radioterapia Oncologica, 27-29 September, 2017, Rimini, Italy.
107. *First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study*. Abstract (poster) No. 961P, **Annals of Oncology** 2019 Oct;30:v389,Supplement 5: 44th European Society for Medical Oncology (ESMO) Congress, 27 September-1 October, 2019, Barcelona, Spain.
108. *CEA and CYFRA 21-1 as Prognostic Biomarkers of Benefit from Nivolumab and as a Tool in Treatment Monitoring in Advanced NSCLC*. Abstract (oral communication) No. MA03.03, **Journal of Thoracic Oncology** 2019 July;14(10)Supplement:S257: 14th World Conference on Lung Cancer (WCLC), 7-10 September, 2019, Barcelona, Spain.
109. *Soluble programmed death ligand-1 (sPD-L1) in advanced non small cell lung cancer (NSCLC) patients treated with immunocheckpoint inhibitors*. Abstract No. D09, **Tumori Journal** 2019 Nov;105:89-90,Supplement 6: 21th National Congress of Medical Oncology, 25-27 October, 2019: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
110. *CEA and CYFRA 21-1 as prognostic biomarkers of benefit and as a tool in treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors (ICI)*. Abstract No. D32, **Tumori Journal** 2019 Nov;105:102-103,Supplement 6: 21th National Congress of Medical Oncology, 25-27 October, 2019: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
111. *Association between immunorelated adverse events (irAEs) occurrence and clinical feature and outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: data from final analyses of IRAENE*. Abstract No. E01, **Tumori Journal** 2019 Nov;105:117,Supplement 6: 21th National Congress of Medical Oncology, 25-27 October, 2019: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
112. *Safety of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES study*. Abstract No. E03, **Tumori Journal** 2019 Nov;105:118-119,Supplement 6: 21th National Congress of Medical Oncology, 25-27 October, 2019: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
113. *Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PDL1 immune checkpoint inhibitors: the FAMI-L1 study*. Abstract No. R01, **Tumori Journal** 2019 Nov;105:155-156,Supplement 6: 21th National Congress of Medical Oncology, 25-27 October, 2019: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
114. *Possible prognostic role of hypercholesterolemia in advanced cancer patients treated with immune-checkpoint inhibitors*. Abstract (poster) No. R03, **Tumori Journal** 2019 Nov;105:157,Supplement 6: 21th National Congress of Medical Oncology, 25-27 October, 2019: Associazione Italiana Oncologia Medica (AIOM), Roma, Italy.
115. *Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC*. Abstract (poster) No. 10P, **Annals of Oncology** 2019 Dec;30:xi3,Supplement 11: European Society for Medical Oncology (ESMO) Immuno-

Oncology Congress, 11-14 December, 2019, Geneva, Switzerland.

116. *Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study*. Abstract (poster) No. TPS596, **Journal of Clinical Oncology** 2020;38,Supplement 6S: 2020 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 13-15, 2020; San Francisco, CA, USA.
117. *Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study*. Abstract (oral communication) No. 613, **Journal of Clinical Oncology** 2020;38,Supplement 6S: 2020 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 13-15, 2020; San Francisco, CA, USA.
118. *Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7)*. Abstract (poster) No. 691, **Journal of Clinical Oncology** 2020;38,Supplement 6S: 2020 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 13-15, 2020; San Francisco, CA, USA.
119. *Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study*. Abstract (poster) No. 751, **Journal of Clinical Oncology** 2020;38,Supplement 6S: 2020 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 13-15, 2020; San Francisco, CA, USA.
120. *Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC)*. Abstract (poster) No. 752, **Journal of Clinical Oncology** 2020;38,Supplement 6S: 2020 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 13-15, 2020; San Francisco, CA, USA.
121. *Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14)*. Abstract No. e17093, **Journal of Clinical Oncology** 2020;38,Supplement: 2020 American Society of Clinical Oncology (ASCO) 56th Annual (Virtual) Meeting; May 29-31, 2020; McCormick Place; Chicago, Illinois, USA.
122. *Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study*. Abstract No. e17081, **Journal of Clinical Oncology** 2020;38,Supplement: 2020 American Society of Clinical Oncology (ASCO) 56th Annual (Virtual) Meeting; May 29-31, 2020; McCormick Place; Chicago, Illinois, USA.
123. *Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O): A real-world study on behalf of Meet-URO group (MeetUro-7b)*. Abstract No. e17088, **Journal of Clinical Oncology** 2020;38,Supplement: 2020 American Society of Clinical Oncology (ASCO) 56th Annual (Virtual) Meeting; May 29-31, 2020; McCormick Place; Chicago, Illinois, USA.
124. *Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)*. Abstract (poster) No. 739P, **Annals of Oncology** 2020 Sep;31:S576,Supplement 4: European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.
125. *Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study*. Abstract (poster) No. 802TiP, **Annals of Oncology** 2020 Sep;31:S607-608,Supplement 4: European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.
126. *The prognostic role of "drug score" on the outcome of advanced cancer patients treated with immune checkpoint inhibitors*. Abstract (poster) No. 1040P, **Annals of Oncology** 2020 Sep;31:S714-S715,Supplement 4: European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.
127. *Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients* (https://www.annalsofoncology.org/article/S0923-7534(20)41318-3/fulltext). Abstract (oral communication) No. 1929O, **Annals of Oncology** 2020 Sep;31:S1092,Supplement 4: European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.
128. *Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study*. Abstract (oral communication) No. LBA82, **Annals of Oncology** 2020 Sep;31:S1209,Supplement 4: European Society for Medical Oncology (ESMO) Virtual Congress, September 19-21, 2020.
129. *INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The multicenter, prospective, observational INVIDIa-2 study (a FICOG study)*. Abstract (oral communication (https://congresso.aiom.it/virtual-meeting-informazioni/sabato-31-ottobre-2020-auditorium-orario-17%3A00-18%3A30/1,736,0,)) No. LBA01, **Tumori Journal** 2020 Nov;106:1,Supplement 2: 22nd National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 30-November 1, 2020.
130. *Liquid biopsy and PET parameters as predictive factors of osimertinib treatment in advanced EGFR-mutated NSCLC***.** Abstract (poster) No. A12, **Tumori Journal** 2020 Nov;106:10-11,Supplement 2: 22nd National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 30-November 1, 2020.
131. *COVID-19 analysis from the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge) – a FICOG study***.** Abstract (oral communication (https://congresso.aiom.it/virtual-meeting-informazioni/sabato-31-ottobre-2020-sala-minerva-orario-15%3A30-16%3A30/1,726,0,)) No. D01, **Tumori Journal** 2020 Nov;106:64-65,Supplement 2: 22nd National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 30-November 1, 2020.
132. *The impact of drugs modulating microbiota on the outcome of advanced cancer patients treated with immune checkpoint inhibitors. A new prognostic "drug score"*. Abstract (poster) No. T10, **Tumori Journal** 2020 Nov;106:180-181,Supplement 2: 22nd National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 30-November 1, 2020.
133. *Influenza-like syndrome and Sars-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge) – a FICOG study*. Abstract (poster) No. 363: 7th European Scientific Working Group on Influenza - Virtual Edition, December 6-9, 2020.
134. *Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The BEYOND study (Meet-Uro19)*. Abstract (poster) No. 319, **Journal of Clinical Oncology** 2021;39,Supplement 6S: 2021 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 11-13, 2021; Virtual Edition.

135. *Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21)*. Abstract (poster) No. 320, **Journal of Clinical Oncology** 2021;39,Supplement 6S: 2021 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 11-13, 2021; Virtual Edition.
136. *A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study)*. Abstract (poster) No. 401, **Journal of Clinical Oncology** 2021;39,Supplement 6S: 2021 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 11-13, 2021; Virtual Edition.
137. *Liquid Biopsy and PET Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.* Abstract (poster) No. P76.52, **Journal of Thoracic Oncology** 2021 March;16(3S):S610: 21st World Conference on Lung Cancer (WCLC 2020) Worldwide Virtual Event, 28-31 January, 2021, Singapore.
138. *Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients.* Abstract (poster) No. 117P, **Journal of Thoracic Oncology** 2021 April;16(4S):S761-S762: European Lung Cancer Conference (ELCC) Virtual Congress, 25-27 March, 2021.
139. *Programmed death ligand-1 (PD-L1) expression in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in NIVES study.* Abstract No. 4558, **Journal of Clinical Oncology** 2021;39(15),Supplement: 2021 American Society of Clinical Oncology (ASCO) 57th Annual Meeting; Jun 4-8, 2021; Virtual Edition.
140. *A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information - NCT03354884*. Abstract No. 4571, **Journal of Clinical Oncology** 2021;39(15),Supplement: 2021 American Society of Clinical Oncology (ASCO) 57th Annual Meeting; Jun 4-8, 2021; Virtual Edition.
141. *Feasibility of multiple immunoexpression assay for immune tumor microrvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study)*. Abstract No. e16545, **Journal of Clinical Oncology** 2021;39(15),Supplement: 2021 American Society of Clinical Oncology (ASCO) 57th Annual Meeting; Jun 4-8, 2021; Virtual Edition.
142. *Fusion 3D gross sampling method to overcome heterogeneity in clear cell renal cell carcinoma (ccRCC) and grading angiogenic versus immune signatures*. Abstract No. e16565, **Journal of Clinical Oncology** 2021;39(15),Supplement: 2021 American Society of Clinical Oncology (ASCO) 57th Annual Meeting; Jun 4-8, 2021; Virtual Edition.
143. *A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)*. Abstract (oral communication) No. 654MO, **Annals of Oncology** 2021 Sep;32:S680,Supplement 5: European Society for Medical Oncology (ESMO) Virtual Congress, September 16-21, 2021.
144. *Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)*. Abstract (poster) No. 696P, **Annals of Oncology** 2021 Sep;32:S709,Supplement 5: European Society for Medical Oncology (ESMO) Virtual Congress, September 16-21, 2021.
145. *A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy*. Abstract (poster) No. 1352P, **Annals of Oncology** 2021 Sep;32:S1027,Supplement 5: European Society for Medical Oncology (ESMO) Virtual Congress, September 16-21, 2021.
146. *High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC*. Abstract (poster) No. P57.08 **Journal of Thoracic Oncology** 2021 Oct;16(10): S1140,Supplement: 22nd World Conference on Lung Cancer (WCLC) Worldwide Virtual Event, September 8-14, 2021.
147. *Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) treated with first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)***.** Abstract (poster) No. C04, **Tumori Journal** 2021 Oct;107:43-44,Supplement 2: 23th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 22-24, 2021.
148. *A phase 2 prospective trial of Cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: the BONSAI trial (Meeturo 2) Clinical trial information: NCT03354884*. Abstract No. C07, **Tumori Journal** 2021 Oct;107:45-46,Supplement 2: 23th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 22-24, 2021.
149. *The prognostic stratification of the Meet-URO score compared with the IMDC score in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving cabozantinib*. Abstract (poster) No. C10, **Tumori Journal** 2021 Oct;107:47-48,Supplement 2: 23th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 22-24, 2021.
150. *Multitarget immunohistochemical (mIHC) assessment of the Immune Tumor MicroEnvironment (I-TME) in responder versus (vs) nonresponder metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (the Meet-URO 18 study)*. Abstract No. C17, **Tumori Journal** 2021 Oct;107:51-52,Supplement 2: 23th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)] – Virtual Meeting, October 22-24, 2021.
151. *Efficacy and toxicity of single agent immunecheckpoint inhibitors among adults with cancer aged ≥ 80 years: a multicenter international cohort study*. Abstract (poster) No. 239 **Journal for ImmunoTherapy of Cancer** 2021 Nov;9:A257,Supplement 2: 36th annual meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14, 2021; Washington, D.C., USA.
152. *Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients*. Abstract (poster) No. 17P, **Annals of Oncology** 2021 Dec;32:s1380-s1381,Supplement 7: European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, 8-11 December, 2021, Online Congress.
153. *Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status*. Abstract (poster) No. 10P, **Annals of Oncology** 2021 Dec;32:s1378,Supplement 7: European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, 8-11 December, 2021, Online Congress.
154. *Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations*. Abstract (poster) No. 349, **Journal of Clinical Oncology** 2022;40,Supplement 6S: 2022 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 17-19, 2022; San Francisco (and Online), CA, USA.
155. *Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors inrenal cell carcinoma (TACITO trial)*. Abstract (poster) No. TPS407, **Journal of Clinical Oncology** 2022;40,Supplement 6S: 2022 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 17-19, 2022; San Francisco (and Online), CA, USA.
156. *First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.* Abstract (poster and oral presentation) No. 439, **Journal of Clinical Oncology** 2022;40,Supplement 6S: 2022 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 17-19, 2022; San Francisco (and Online), CA, USA.

157. *Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first line immunotherapy-based regimens*. Abstract (poster) No. 165P, **Annals of Oncology** 2022 Apr;33:S105-S110,Supplement 2: European Lung Cancer Congress, 30 March-02 April, 2022, Online Congress.
158. *The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (Δ-Meet-URO analysis)*. Abstract (poster) No. 4534, **Journal of Clinical Oncology** 2022;40(16),Supplement: 2022 American Society of Clinical Oncology (ASCO) 58th Annual Meeting; June 3-7, 2022; McCormick Place; Chicago, Illinois, USA.
159. *The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study*. Abstract (poster) No. 4535, **Journal of Clinical Oncology** 2022;40(16),Supplement: 2022 American Society of Clinical Oncology (ASCO) 58th Annual Meeting; June 3-7, 2022; McCormick Place; Chicago, Illinois, USA.
160. *Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?*. Abstract No. e16512, **Journal of Clinical Oncology** 2022;40(16),Supplement: 2022 American Society of Clinical Oncology (ASCO) 58th Annual Meeting; June 3-7, 2022; McCormick Place; Chicago, Illinois, USA.
161. *First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial*. Abstract No. A0906, **European Urology** 2022;81:S1335-S1336,Supplement 1: 2022 European Association Urology (EAU) 37th Annual Congress; July 1 - 4, 2022; Amsterdam, Netherlands.
162. *Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer*. Abstract (poster) No. P1.15-04 **Journal of Thoracic Oncology** 2022 Sep;17(9):S120-S121,Supplement: 23th World Conference on Lung Cancer (WCLC), August 6-9, 2022; Vienna, Austria.
163. *Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial*. Abstract (oral communication) No. LBA4, **Annals of Oncology** 2022 Sep;33:S1430,Supplement 7: European Society for Medical Oncology (ESMO) Congress, 9-13 September, 2022, Paris, France.
164. *Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study*. Abstract (poster) No. 1476P, **Annals of Oncology** 2022 Sep;33:S1221-S1222,Supplement 7: European Society for Medical Oncology (ESMO) Congress, 9-13 September, 2022, Paris, France.
165. *Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)*. Abstract (poster) No. 1462P, **Annals of Oncology** 2022 Sep;33:S1214-S1215,Supplement 7: European Society for Medical Oncology (ESMO) Congress, 9-13 September, 2022, Paris, France.
166. *First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): the ARIES trial*. Abstract (oral communication) No. 02, **Tumori Journal** 2022 Oct;108:2,Supplement 4: 24th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], October 1-3, 2022, Roma, Italy.
167. *Longitudinal monitoring of radiomic and blood immune-inflammatory descriptors as a non-invasive approach to predict ICI efficacy in advanced NSCLC patients*. Abstract (poster) No. A16, **Tumori Journal** 2022 Oct;108:13-14,Supplement 4: 24th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], October 1-3, 2022, Roma, Italy.
168. *Immune tumor microenvironment (i-TME) analyses in metastatic renal cell carcinoma (mRCC) patients (pts) treated with second line nivolumab: results from the MeeT-URO 18 study*. Abstract (oral communication) No. D01, **Tumori Journal** 2022 Oct;108:84-85,Supplement 4: 24th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], October 1-3, 2022, Roma, Italy.
169. *Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination. NEMESIA (non clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (MeeT-URO 23A)*. Abstract (poster) No. D18, **Tumori Journal** 2022 Oct;108:94-95,Supplement 4: 24th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], October 1-3, 2022, Roma, Italy.
170. *The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors*. Abstract (poster) No. S04, **Tumori Journal** 2022 Oct;108:143-144,Supplement 4: 24th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], October 1-3, 2022, Roma, Italy.
171. *Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors*. Abstract (poster) No. 91, **Journal for ImmunoTherapy of Cancer** 2022 Nov;10:A99-A100,Supplement 2: 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), November 8-12, 2022; Boston, MA, USA.
172. *Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors*. Abstract No. 112, **Journal for ImmunoTherapy of Cancer** 2022 Nov;10:A122-A124,Supplement 2: 37th annual meeting of the Society for Immunotherapy of Cancer (SITC), November 8-12, 2022; Boston, MA, USA.
173. *Nivolumab + ipilimumab (NIVO + IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie: résultats de l'étude de phase 3 randomisée Checkmate 914 (CM914)*. Abstract (oral communication) No. CO-095, **Progrès en Urologie – FMC** 2022 Nov;32(3):S88,Supplement: 116e Congrès Français D'urologie [Association Française d'Urologie (AFU)], November 16-19, 2022, Paris, France.
174. *Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors*. Abstract No. 238P (poster), **Immuno-Oncology and Technology** 2022 Dec;16:100227,Supplement 1: European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, 7-9 December, 2022, Geneva, Switzerland.
175. *Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT)*. Abstract (oral communication) No. 5, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
176. *Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial)*. Abstract (poster) No. 171,

Journal of Clinical Oncology 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.

177. *READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)*. Abstract (poster) No. 469, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
178. *Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9)*. Abstract (poster) No. 637, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
179. *Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study*. Abstract (poster) No. 638, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
180. *Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9)*. Abstract (poster) No. 647, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
181. *Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9*. Abstract (poster) No. 648, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
182. *A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-URO 8 study)*. Abstract (poster) No. 712, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
183. *Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study*. Abstract (poster) No. 714, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
184. *Correlation of the immune tumor microenvironment (I-TME) with gene expression profiles as prognostic and predictive factors in patients (pts) with metastatic renal carcinoma (mRCC) treated with immunotherapy (Meet-URO 18 I-TME study)*. Abstract (poster) No. TPS753, **Journal of Clinical Oncology** 2023;41,Supplement 6S: 2023 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; February 25-27, 2023; San Francisco (and Online), CA, USA.
185. *Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study*. Abstract No. A1033, **European Urology** 2023;83:S1490-S1491,Supplement 1: 2023 European Association Urology (EAU) 38th Annual Congress; March 10 - 13, 2023; Milan, Italy.
186. *Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial*. Abstract (poster) No. 4578, **Journal of Clinical Oncology** 2023;41(16),Supplement: 2023 American Society of Clinical Oncology (ASCO) 59th Annual Meeting; May 31 - June 4, 2023; McCormick Place; Chicago, Illinois, USA.
187. *Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune combinations with a focus on the role of cytoreductive nephrectomy*. Abstract (oral communication) No. 34, **Anticancer Research** 2023;43(10):4747-4778, 33rd Annual Meeting Of The Italian Society of Uro-Oncology (SIUrO); October 5-7, 2023, Parma, Italy.
188. *Papillary Renal Cell Carcinoma (pRCC): Outcomes of patients receiving first-line immune-based combinations or Tyrosine Kinase Inhibitors (TKIs) from the ARON-1 study*. Abstract No. A0839, **European Urology** 2024;85:S1490-S1491,Supplement 1: 2024 European Association Urology (EAU) 39th Annual Congress; April 5 - 8, 2024; Paris, France.
189. *Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study*. Abstract (poster) No. 1599P, **Annals of Oncology** 2023 Oct;34:S888,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.
190. *Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study*. Abstract (oral communication) No. 1884MO, **Annals of Oncology** 2023 Oct;34:S1013,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.
191. *Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)*. Abstract (poster) No. 1895P, **Annals of Oncology** 2023 Oct;34:S1020,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.
192. *Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations*. Abstract (poster) No. 1897P, **Annals of Oncology** 2023 Oct;34:S1021,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.
193. *Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8)*. Abstract (poster) No. 1901P, **Annals of Oncology** 2023 Oct;34:S1022-S1023,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.
194. *Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study*. Abstract (poster) No. 2125P, **Annals of Oncology** 2023 Oct;34:S1110,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.
195. *Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial*.

Abstract (poster) No. 2368P, **Annals of Oncology** 2023 Oct;34:S1205,Supplement 2: European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023, Madrid, Spain.

196. *Phase II study of avelumab (ave) plus intermittent axitinib (axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). the TIDE-A study*. Abstract (oral communication) No. A02, **Tumori Journal** 2023 Nov;109:5,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
197. *Immunohistochemical (IHC) analyses of the immune tumor microenvironment (i-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: secondary analyses of the Meet-URO 18 study*. Abstract (poster) No. A15, **Tumori Journal** 2023 Nov;109:14,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
198. *Time to treatment failure (TTF) and treatment beyond progression (TBP) as survival outcome and therapeutic strategy of clinical benefit in pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab: a subanalysis of Meet-URO 15 study*. Abstract No. A30, **Tumori Journal** 2023 Nov;109:24,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
199. *Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations with a focus on the role of cytoreductive nephrectomy: an analysis from ARON-1 project*. abstract no. A37, **Tumori Journal** 2023 Nov;109:28,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
200. *Use of concomitant proton pump inhibitors, statins, or metformin in patients treated with pembrolizumab for advanced urothelial carcinoma: data from the ARON-2 retrospective study*. Abstract (poster) No. A40, **Tumori Journal** 2023 Nov;109:30,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
201. *Adjusted skeletal muscle index (ASMI) correlates with outcome in metastatic renal cancer cell (mRCC) patients (pts) treated with first line (1L) immunotherapy (IT)*. Abstract No. A57, **Tumori Journal** 2023 Nov;109:40,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
202. *Clinical relevance of first-line tyrosine kinase inhibitor (TKI) choice in metastatic renal cell carcinoma (mRCC) patients (pts) receiving second-line nivolumab (Meet-URO 15 study)*. Abstract No. A59, **Tumori Journal** 2023 Nov;109:41,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
203. *Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: a retrospective single-center observational study*. Abstract No. B30, **Tumori Journal** 2023 Nov;109:63-64,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
204. *Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immune-inflammatory profiling*. Abstract No. B43, **Tumori Journal** 2023 Nov;109:71-72,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
205. *Potential role of hypovitaminosis d in patients with cancer treated with immune checkpoint inhibitors (PROVIDENCE): a prospective observational study*. Abstract No. R13, **Tumori Journal** 2023 Nov;109:247-248,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
206. *The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors*. Abstract No. R35, **Tumori Journal** 2023 Nov;109:261,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
207. *Efficacy-toxicity relationship analysis of cabozantinib (cabo) plus durvalumab (durva) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (CT): interim results from the phase 2 ARCADIA trial*. Abstract No. S14, **Tumori Journal** 2023 Nov;109:291,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
208. *Efficacy-toxicity relationship analysis of cabozantinib (cabo) plus durvalumab (durva) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (CT): interim results from the phase 2 ARCADIA trial*. Abstract (poster) No. S14, **Tumori Journal** 2023 Nov;109:291,Supplement 2: 25th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 10-12, 2023, Roma, Italy.
209. *Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)*. Abstract (poster) No. 558, **Journal of Clinical Oncology** 2024;42,Supplement 4: 2024 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; January 25-27, 2024; San Francisco (and Online), CA, USA.
210. *International multicenter real-world registry for patients with metastatic renal cell carcinoma: Meet-URO 33 study (REGAL study)*. Abstract (poster) No. TPS485, **Journal of Clinical Oncology** 2024;42,Supplement 4: 2024 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; January 25-27, 2024; San Francisco (and Online), CA, USA.
211. *Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study)*. Abstract (poster) No. TPS494, **Journal of Clinical Oncology** 2024;42,Supplement 4: 2024 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; January 25-27, 2024; San Francisco (and Online), CA, USA.
212. *Efficacy of perioperative pembrolizumab treatment in patients with resectable metastases from kidney cancer: The PE-PE study*. Abstract (poster) No. TPS495, **Journal of Clinical Oncology** 2024;42,Supplement 4: 2024 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; January 25-27, 2024; San Francisco (and Online), CA, USA.
213. *Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (Meet-URO 31)*. Abstract (poster) No. TPS498, **Journal of Clinical Oncology** 2024;42,Supplement 4: 2024 American Society of Clinical Oncology (ASCO) Genitourinary Symposium; January 25-27, 2024; San Francisco (and Online), CA, USA.
214. *Multiomics approach for patients stratification and novel target identification in metastatic clear cell renal Carcinoma (MeetUro 31)*. Accepted at International Kidney Cancer Symposium 2024 (April 18 – 20, 2024), Stiges, Spain.
215. *First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study*. Abstract (poster) No. 4529, **Journal of Clinical Oncology** 2024;42(16),Supplement: 2024 American Society of Clinical Oncology (ASCO) 60th Annual Meeting; May 31 - June 4, 2024; McCormick Place; Chicago, Illinois, USA.
216. *Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients.* Abstract (poster) No. 1328P, **Annals of Oncology** 2024 Oct;35:S844,Supplement 2: European Society for Medical

Oncology (ESMO) Congress, September 13-17, 2024, Barcelona, Spain.

217. *Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)*. Abstract (poster) No. 1716P, **Annals of Oncology** 2024 Oct;35: S1028-S1029,Supplement 2: European Society for Medical Oncology (ESMO) Congress, September 13-17, 2024, Barcelona, Spain.
218. *Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis*. Abstract (poster) No. 1981P, **Annals of Oncology** 2024 Oct;35:S1146,Supplement 2: European Society for Medical Oncology (ESMO) Congress, September 13-17, 2024, Barcelona, Spain.
219. *Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)*. Abstract (poster) No. 2014P, **Annals of Oncology** 2024 Oct;35:S1161,Supplement 2: European Society for Medical Oncology (ESMO) Congress, September 13-17, 2024, Barcelona, Spain.
220. *Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial*. Abstract (oral communication) No. LBA77, **Annals of Oncology** 2024 Oct;35:S1264,Supplement 2: European Society for Medical Oncology (ESMO) Congress, September 13-17, 2024, Barcelona, Spain.
221. *Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study*. Abstract No. EP.15B.05, **Journal of Thoracic Oncology** 2024 Oct;19(10):S705-S706,Supplement: World Conference on Lung Cancer (WCLC) 2024, September 7-10, 2024, San Diego, CA (US).
222. *External validation of the GRade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma*. Abstract (oral communication) No. IUCS20754-83 – Merit Award, **Therapeutic Advances in Urology** 2024 Sept;16:9-10,Supplement: Second International Urology Cancer Summit (IUCS) 2024, September 27, 2024, Portsmouth, UK.
223. *External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy*. Abstract (oral communication) No. IUCS20761-50 – Merit Award, **Therapeutic Advances in Urology** 2024 Sept;16:13-14,Supplement: Second International Urology Cancer Summit (IUCS) 2024, September 27, 2024, Portsmouth, UK.
224. *REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden*. Abstract (poster) No. P254, **European Urology Open Science** 2024 Nov;69:321,Supplement 2: 16th European Multidisciplinary Congress on Urological Cancers 7-10 November 2024, Lisbon, Portugal.
225. *Overall survival (OS) results in phase II Trial of Cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non- UC variant histologies (VH) after platinum chemotherapy (ARCADIA)*. Abstract (oral communication) No. D01, **Tumori Journal** 2024 Nov;110:103,Supplement 2: 26th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 08-10, 2024, Roma, Italy.
226. *Correlation between body composition (BC) and outcomes in mRCC patients (pts) in first line therapy (1L tp)*. Abstract No. D26, **Tumori Journal** 2024 Nov;110:120,Supplement 2: 26th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 08-10, 2024, Roma, Italy.
227. *Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study*. Abstract No. D36, **Tumori Journal** 2024 Nov;110:126,Supplement 2: 26th National Congress of Medical Oncology [Associazione Italiana Oncologia Medica (AIOM)], November 08-10, 2024, Roma, Italy.

B. Articoli/Capitoli

[https://www.ncbi.nlm.nih.gov/myncbi/1LK3dbZ1NCa5-/bibliography/public/ (https://www.ncbi.nlm.nih.gov/myncbi/1LK3dbZ1NCa5-/bibliography/public/) oppure https://pubmed.ncbi.nlm.nih.gov/?term=%22Buti%20s%22%20NOT%20%22buti%20sm%22%20NOT%20%22buti%20sara%22%20NOT%20%22buti%20salvador%22%20NOT%2 (https://pubmed.ncbi.nlm.nih.gov/?term=%22Buti%20s%22%20NOT%20%22buti%20sm%22%20NOT%20%22buti%20sara%22%20NOT%20%22buti%20salvador%22%20NOT%2 Links per pubblicazioni indicizzate su PubMed]

[https://scholar.google.it/citations?user=XFNSuo4AAAAJ&hl=it (https://scholar.google.it/citations?user=XFNSuo4AAAAJ&hl=it) Link per pubblicazioni indicizzate su Google Scholar]

[https://orcid.org/0000-0003-0876-0226 (https://orcid.org/0000-0003-0876-0226) Link per pubblicazioni indicizzate su ORCID]

[https://publons.com/researcher/1406270/sebastiano-buti/publications/ (https://publons.com/researcher/1406270/sebastiano-buti/publications/) Link per pubblicazioni indicizzate su Publons – Web of Science]

[https://www.scopus.com/authid/detail.uri?authorId=55883521400 (https://www.scopus.com/authid/detail.uri?authorId=55883521400) Link per pubblicazioni indicizzate su Scopus, accessibile previa registrazione]

1. *MINDACT trial (Microarray In Node negative Disease may Avoid Chemotherapy): utilizzo del profilo di espressione genica nella selezione delle pazienti con cancro della mammella per la chemioterapia adiuvante*. **Scenari**-Rivista di Oncologia Pratica e Sperimentale. 4;61-66 (2005).
2. *Immunotherapy options in metastatic renal cell cancer: where we are and where we are going*. **Expert Review of Anticancer Therapy**. Oct;6(10),1459-1472 (2006).
3. *Interleuchina-2 (IL-2) più Interferone-α (IFN-α) a basse dosi come terapia adiuvante nel carcinoma a cellule renali (RCC) operabile. Uno studio indipendente di fase III, randomizzato, multicentrico, del Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)*. **GOIRC News** - notiziario del gruppo oncologico italiano di ricerca clinica n. 3 (2006).
4. *Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report*. **Anti-Cancer Drugs**. Mar;18(3):297-300 (2007).
5. *A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer*. **Tumori**. May-Jun;93(3):244-7 (2007).

6. *Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC)*. **Journal of Immunotherapy**. Oct;30(7):780-786 (2007).
7. *Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2 as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial*. **Acta Bio Medica**. 78(3):204-209 (2007).
8. *Terapia adiuvante,* capitolo 6.6, pag. 178-190, **Basi scientifiche per la definizione di linee-guida in ambito clinico per il Carcinoma Renale** (https://www.iss.it/home?p_p_id=com_liferay_portal_search_web_portlet_SearchPortlet&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_com_liferay_portsite&_com_liferay_portal_search_web_portlet_SearchPortlet_assetEntryId=976429&_com_liferay_portal_search_web_portlet_SearchPortlet testo pubblicato da Alleanza Contro il Cancro (2008) per l'Istituto Superiore di Sanità.
9. *Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile*. **Oncology**. 76:69-76 (2009).
10. *Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.* **Cancer Immunology, Immunotherapy**. Apr;59(4):553-561 (2010).
11. *Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5- fluorouracil regimen*. **Tumori**. Jan-Feb;96(1):48-53 (2010).
12. *Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: an Italian Oncology Group for Clinical Research (GOIRC) study.* **Journal of Immunotherapy**. Oct;30(7):780-786 (2010).
13. *Renal Cell Cancer: State of the Art in Adjuvant Therapy.* **Recent Patents on Anti Cancer Drug Discovery**. Nov 1;5(3):242-50 (2010).
14. *Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.* **Cancer Chemotherapy and Pharmacology**. Jan;67(1):41-48 (2011).
15. *Italian Survey on Adjuvant treatment of non-small cell lung cancer (ISA)*. **Lung Cancer**. Jul;73(1):78-88 (2011).
16. *Impressive response with imatinib in a heavily pretreated patient with metastatic c-kit mutated thymic carcinoma*. **Journal of Clinical Oncology**. Nov 20;29(33):e803-805 (2011).
17. *Changes in lymphocyte count induced by repeated cycles with low doses interleukin-2 and interferon-α in 146 patients with renal cell carcinoma.* **Tumori**. Jan-Feb;98(1):45-52 (2012).
18. *Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer on hemodialysis: a retrospective italian survey*. **British Journal of Urology International**. Sep;110(5):692-698. (2012).
19. *Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors*. **Annals of Oncology**. Sep;23(9):2409-2414 (2012).
20. *Adjuvant Therapy for Renal Cell Carcinoma*. **Topics in Anti-Cancer Research.** E-book: Vol 1; chapter 4:113-139 (2012).
21. *Systemic adjuvant therapies in renal cell carcinoma*. **Oncology Reviews**. Vol 6(2);e18:145-152 (2012)
22. *Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer (NSCLC): results of GOIRC 02-2006 randomized phase II study and pooled analysis with NVALT7 trial.* **Journal of Clinical Oncology**. Dec 20;30(36):4501-4507 (2012).
23. *A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.* **Acta Bio Medica**. Aug;83(2):88-94 (2012).
24. *When a thymic carcinoma "becomes" a GIST*. **Lung Cancer**. Apr;80(1):106-108 (2013).
25. *Does the cetuximab plus paclitaxel combination deserve to be studied in a phase III trial?* **Journal of Clinical Oncology**. Apr 20;31(12):1613-1614 (2013).
26. *Chemotherapy in metastatic renal cell carcinoma today? A systematic review*. **Anti-Cancer Drugs**. Jul;24(6):535-54 (2013).
27. *Colony-stimulating factors for febrile neutropenia*. **New England Journal of Medicine**. Jul 18;369(3):285 (2013).
28. *Axitinib dose titration. What's the limiting factor?* **The Lancet Oncology**. Nov;14(12):1152-1154 (2013).
29. *Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.* **Tumori**. Jan-Feb;100(1):20e-3e (2014).
30. *A wide skull osteolytic metastasis in advanced breast cancer*. **Acta Bio Medica**. Jan;85(1):85-87 (2014).
31. *BOLERO-3 results: pharmacological activity or pharmacokinetic effect?* **The Lancet Oncology**. Jul;15(8):e304 (2014).
32. *Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan*. **Lung Cancer**. Oct;86(1):91-95 (2014).
33. *Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-α) in operable renal cell carcinoma (RCC). A phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)*. **Journal of Immunotherapy**. Nov-Dec;37(9):440-447 (2014).
34. *Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy*. **Cancers**. Sep 30;6(4):2035-2048 (2014).
35. *Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5 years) metastatic renal cell carcinoma*. **Journal of Urology**. J Urol. Jan;193(1):41-7 (2015).
36. *Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?* **Future Oncology**. Jan;11(1):107-219 (2015).
37. *Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients*. **Future Oncology**. Jan;11(6):965-973 (2015).
38. *Retroperitoneal cystoadenocarcinoma: a case report with literature review*. **Acta Bio Medica**. Jan;86(1):97-105 (2015).
39. *Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH*. **Tumori**. Apr 28;101(2):e51-3 (2015).
40. *Dose finding/phase II trial: bevacizumab, immunotherapy and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating t-regulatory cells (t-reg).* **Targeted Oncology**. Jun;10(2):277-286 (2015).
41. *Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors*. **Annals of Surgical Oncology**. Jun;22(6):2094-2100 (2015).
42. *Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.* **Lung Cancer**. Jun;88(3):319-324 (2015).
43. *Very late recurrence of an apparently "benign" pheochromocytoma: a case report*. **Journal of Cancer Research and Therapeutics**. Oct-Dec;11(4):1036 (2015).

44. *ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients*. **Diagnostic Cytopathology**. Nov;43(11):941-946 (2015).
45. *Combination therapy in kidney cancer: the next revolution?* **The Lancet Oncology**. Nov;16(15):1441-1442 (2015).
46. *Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy*. **Targeted Oncology**. Dec;10(4):517-522 (2015).
47. *Upfront chemohormonal therapy for prostate cancer: neutropenia and G-CSF use*. **Acta Biomedica**. Jan;87(1):108-109 (2016).
48. *AR-V7 and prostate cancer: the watershed for treatment selection?* Submitted to **Cancer Treatment Reviews**. Feb;43:27-35 (2016).
49. *Drug-Induced Megaloblastic Anemia*. **New England Journal of Medicine**. Feb 18;374(7):695-6 (2016).
50. *Rupture and Distal Migration of a Central Venous Catheter*. **Open Journal of Clinical and Medical Case Reports**. Feb;2(4):1079 (2016)
51. *Non-clear cell renal carcinoma therapy: handle with care*. **The Lancet Oncology**. Mar;17(3):270-1 (2016).
52. *LA PRATICA CLINICA - Everolimus nel carcinoma renale papillare*. Caso clinico online pubblicato sul sito renalcancer.it, http://renalcancer.it/la-pratica-clinica/everolimus-carcinoma-papillare/ (http://renalcancer.it/la-pratica-clinica/everolimus-carcinoma-papillare/) (marzo 2016).
53. *Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma of the bladder: a matter of possible pharmacological interaction*. BMC cancer. Aug 12;16:626 (2016).
54. *Outcome and safety of sorafenib in metastatic renal cell carcinoma dialysis patients: a systematic review*. **Clinical Genitourinary Cancer**. Aug;14(4):277-83 (2016).
55. *The "nivolution" in renal cell carcinoma: behind the scenes of clinical trials?* **Future Oncology**. Sep;12(18):2061-3 (2016).
56. *Inside the 2016 ASCO Genitourinary Cancers Symposium: Part 1 – Kidney Cancer*. **Future Oncology**. Sep;12(17):1967-1970 (2016).
57. *Inside the 2016 ASCO Genitourinary Cancers Symposium: Part 2 – Prostate and Bladder Cancer*. Future Oncology. Sep;12(17):1971-1974 (2016).
58. *Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy*. **Core Evidence.** Sep;2016(11):23-36 (2016).
59. *Cabozantinib in RCC: only a METEOR or a rising star?* **Acta Biomedica**. May;87(2):224-225 (2016).
60. *Pazopanib in renal cell carcinoma dialysis patients: a mini-review and a case report*. **Current Drugs Targets**. 17(15):1755-1760 (2016).
61. *Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma*. **Oncotarget**. May 31;7(22):33381-33390 (2016).
62. *Primary retroperitoneal cystoadenocarcinoma: a systematic review*. **Gynecologic and Obstetric Investigation**. 81(5):385-93 (2016).
63. *Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder*. **Tumori Journal**. Jan 21;103(1):66-71 (2017).
64. *From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis*. World Journal of Clinical Oncology. February 10; 8(1): 37-53 (2017).
65. *Analysis of a panel of druggable gene mutations and of ALK and PDL-1 expression in a series of thymic epithelial tumors (TETs)*. Lung Cancer. Feb;104:24-30 (2017).
66. *Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?* PLoS One. Feb 27;12(2):e0172341 (2017).
67. *Plasma genotyping for EGFR T790M in non-small cell lung cancer: ready for clinical practice?* Translational Cancer Research. Feb;6(suppl1):S61-S64 (2017).
68. *Pazopanib nel trattamento del carcinoma renale metastatico: dalle linee guida alla pratica clinica – Risultati di sei "Minifaculties" sui modelli di trattamento del mRCC in Italia.* ABOUT MEDICINE - Spotlight. Mar;5(4):1-16 (2017).
69. *Is Cabozantinib Really Better Than Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma?* Journal of Clinical Oncology. Jun 1;35(16):1858-1859 (2017).
70. *"Finding NEMO" in NRAS-mutated melanoma: a step towards a sequential strategy?* The Lancet Oncology. Jun;18(6):e298 (2017).
71. *Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma*. Therapeutics and Clinical Risk Management. Jun 30;13:799-806 (2017).
72. *Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis*. Oncotarget. Aug 7;8(59):100708-100716 (2017).
73. *First-line PAzopanib in NOn-clear cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA study*. Clinical Genitourinary Cancer. Aug;15(4):e609-e614 (2017).
74. *Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer*. Urologic Oncology: Seminars and Original Investigations. Sep;35(9):541.e7-541.e13 (2017).
75. *Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential*. Therapeutic Advances in Medical Oncology. Oct;9(10):627-636 (2017).
76. *Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population*. Annals of Oncology. Nov 1;28(11):2747-2753 (2017).
77. *The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade*. Immunotherapy. Nov;9(14):1127-1131 (2017).
78. *Feasibility, safety and efficacy of an alternative schedule of sunitinib for the treatment of metastatic renal cell carcinoma patients: a retrospective study.* Drugs in R&D. Dec;17(4):585-596 (2017).
79. *Durvalumab in Stage III Non-Small-Cell Lung Cancer*. New England Journal of Medicine. Mar 1;378(9):869 (2018).
80. *Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study*. Immunotherapy. Jun;10(8):643-655 (2018).
81. *Clinical and hematologic parameters address the outcomes of non-small cell lung cancer patients treated with nivolumab*. Immunotherapy. Jun;10(8):681-694 (2018).
82. *Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian Nivolumab expanded access program*. Future Oncology. Jun;14(14):1347-1354 (2018).
83. *Loss of heterozygosity of key tumor suppressor genes and clinical outcome of advanced renal cancer patients treated with nivolumab.* Immunotherapy. Jul;10(9):743-752 (2018).

84. *Safety and efficacy of cabozantinib in metastatic renal cell carcinoma: real world data from an Italian Managed Access Program (MAP)*. Clinical Genitourinary Cancer. Aug;16(4):e945-e951 (2018).
85. *Patient performance status and cancer immunotherapy efficacy: a meta-analysis*. Medical Oncology. Aug 20;35(10):132 (2018).
86. *The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.* Anti-Cancer Drugs. Aug;29(7):705-709 (2018).
87. *Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature*. **Immunotherapy**. Sep;10(13):1123-1132 (2018).
88. *Profile of atezolizumab in the treatment of metastatic non-small cell lung cancer: patient selection and perspectives*. **Drug Design, Development and Therapy**. Sep 10;12:2857-2873 (2018).
89. *Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date*. **Cancer Management and Research**. Sep 21;10:3773-3780 (2018).
90. *Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)*. **Future Oncology**. Sep;14(22):2223-2224 (2018).
91. *INfluenza Vaccine Indication During anticancer therapy with Immune checkpoint inhibitors: a transversal challenge for patient's counselling – the INVIDIa study*. Immunotherapy. Oct;10(14):1229-1239 (2018).
92. *Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with intermediate and poor risk prognosis?* Clinical Genitourinary Cancer. Oct;16(5):355-359.e1 (2018).
93. *Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series*. **International Journal of Urology.** Oct;25(10):879-886 (2018).
94. *Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma*. Anticancer Research. Oct;38(10):5773-5782 (2018).
95. *Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis*. **Immunotherapy**. Nov;10(15):1303-1313 (2018).
96. *Vaccinazione antinfluenzale durante immunoterapia oncologica con inibitori del checkpoint immunitario PD-1/PD-L1: quali dati abbiamo per la raccomandazione clinica? [Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?]*. **Recenti Progressi in Medicina**. Nov;109(11):1-7 (2018).
97. *First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer*. **New England Journal of Medicine**. Dec 6;379(23):2220-2229 (2018).
98. *A new prognostic model for localized renal cell carcinoma*. **World Journal of Urology**. Jan;37(1):211-212 (2019).
99. *The Circulating Pool of Functionally Competent NK and CD8+ Cells Predicts the Outcome of anti-PD1 Treatment in Advanced NSCLC*. **Lung Cancer**. Jan;127:153-163 (2019).
100. *Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma*. **Immunotherapy**. Jan;11(1):21-35 (2019).
101. *Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Program.* **British Journal of Urology International**. Jan;123(1):98-105 (2019).
102. *Family history of cancer and DNA damage response genes: two sides of the same coin?* **Thoracic Cancer**. Thorac Cancer. Feb;10(2):401 (2019).
103. *Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study*. **Clinical Genitourinary Cancer**. Feb;17(1):e150-e155 (2019).
104. *A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable*. **Journal for ImmunoTherapy of Cancer.** Feb 27;7(1):57 (2019).
105. *Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions.* **Annals of Translational Medicine**. Mar;7(Suppl 1):S54 (2019).
106. *Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.* **Journal for ImmunoTherapy of Cancer**. Apr 3;7(1):99 (2019).
107. *Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker*. **BioMed Research International**. Apr 24;2019:9056417 (2019).
108. *From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.* **Lung Cancer**. May;131:78-85 (2019).
109. *The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes*. **Targeted Oncology**. Jun;14(3):247-252 (2019).
110. *Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.* **The Oncologist**. Jun;24(6):e327-e337 (2019).
111. *Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients*. **Clinical Lung Cancer**. Jul;20(4):237-247.e1 (2019).
112. *Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab*. **Clinical Cancer Research**. Jul 1;25(13):3839-3846 (2019).
113. *State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: when common sense is not enough.* **Critical Reviews in Oncology/Hematology**. Jul;139:87-90 (2019).
114. *Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches"*. **Annals of Translational Medicine**. Jul;7(Suppl 3):S106 (2019).
115. *Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?* **European Urology Oncology**. Jul 19:S2588-9311(19)30099-9 (2019)
116. *The Effect of a treatment delay on outcome in metastatic renal cell carcinoma*. **Urologic Oncology: Seminars and Original Investigations.** Aug;37(8):529.e1-529.e7 (2019).
117. *Cabozantinib in Renal Cell Carcinoma with Brain Metastases: Safety and Efficacy in a Real-World Population*. **Clinical Genitourinary Cancer**. Aug;17(4):291-298 (2019).
118. *A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients*. **Seminars in Oncology**. Aug - Oct;46(4-5):362-371 (2019).

119. *The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?* **Annals of Translational Medicine**. Sep;7(Suppl 6):S190 (2019).
120. *Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: an end-user friendly model for predicting overall survival in surgically treated renal cell carcinoma patients***. Scientific Reports**. Sep 13;9(1):13218 (2019).
121. *Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review.* **Critical Reviews in Oncology/Hematology**. Oct;142:9-15 (2019).
122. *Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature*. **Clinical Genitourinary Cancer**. Oct;17(5):e903-e908 (2019).
123. *Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies*. **Expert Review of Cardiovascular Therapy**. Dec;17(12):917-927 (2019).
124. *Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab*. Acta Biomedica. Dec 23;90(4):468-474 (2019).
125. *Real-world data on Cabozantinib in previously treated patients with metastatic Renal Cell Carcinoma: focus on prognostic factors and sequences*. **Cancers**. Dec 30;12(1) (2019).
126. *Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: the TOGETHER retrospective study*. **Cancer Treatment and Research Communications**. 22:100161 (2020).
127. *Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study*. **Oncoimmunology**. Jan 7;9(1):1710389 (2020).
128. *Unlocking the secret of the obesity paradox in renal tumors***. The Lancet Oncology.** Feb;21(2):194-19 (2020).
129. *Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study*. **Immunotherapy**. Feb;12(2):151-159 (2020).
130. *Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review***. Expert Review of Molecular Diagnostics**. Feb;20(2):169-185 (2020).
131. *Palliative Radiotherapy in Advanced Cancer patients Treated with Immune-ChEckpoint inhibitors: the PRACTICE study.* **Biomedical Reports**. Feb;12(2):59-67 (2020).
132. *A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?* **Anti-Cancer Drugs.** Mar;31(3):211-215 (2020).
133. *Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.* **European Journal of Cancer**. Mar;128:17-26 (2020).
134. *Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis*. **Journal of Clinical Medicine**. May 5;9(5):1351 (2020).
135. *Correlation Between Immuno-Related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, An Italian Multi-institutional Retrospective Study*. **Clinical Genitourinary Cancer**. May 20:S1558-7673(20)30118-X (2020).
136. *Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: A systematic review.* **Therapeutic Advances in Medical Oncology**. May 26;12:1758835920915303 (2020).
137. *CEA and CYFRA 21-1 as prognostic biomarker and as tool for treatment monitoring in advanced NSCLC treated with Immune-Checkpoint Inhibitors.* **Therapeutic Advances in Medical Oncology**. May 26;12:1758835920915303 (2020).
138. *Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions*. **Expert Review of Anticancer Therapy**. Jun;20(6):491-501 (2020).
139. *Predictive Ability for Disease-Free Survival of the GRade, Age, Node and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma.* **Current Urology**. Jun;14(2):98-104 (2020).
140. *The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors*. **Journal of Immunotherapy**. Jul/Aug;43(6):196-203 (2020).
141. *Abscopal effect after hypo-fractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib*. **Immunotherapy**. Aug;12(12): 869–878 (2020).
142. *Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis*. **Targeted Oncology**. Aug;15(4):495-501 (2020).
143. *Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients*. **Lung Cancer**. Aug 2;148:1-11 (2020).
144. *Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis*. **Clinical and Translational Oncology**. Sep;22(9):1657-1663 (2020).
145. *On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2*. **Annals of Oncology**. Oct;31(10):1415-1416 (2020).
146. *Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation***. Journal for ImmunoTherapy of Cancer**. Oct;8(2):e001403 (2020).
147. *Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy*. **Immunotherapy**. Oct;12(15):1139-1148 (2020).
148. *Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%*. **Cancer Immunology, Immunotherapy**. Nov;69(11):2209-2221 (2020).
149. *Symptomatic COVID-19 in advanced cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.* **Therapeutic Advances in Medical Oncology**. Nov 2;12:1758835920968463 (2020).
150. *Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index*. **European Journal of Cancer**. Nov 16;142:18-28 (2020).
151. *Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta-lesion attenuation difference (ALAD) on contrast-enhanced CT*. **La Radiologia Medica**. Dec;125(12):1280-1287 (2020).

152. *Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report*. **Tumori Journal**. Dec;106(6):NP79-NP83 (2020).
153. *Chemotherapy in Non-Small cell Lung Cancer patients AfteR prior ImmunoTherapY: the multicenter retrospective CLARITY study*. **Lung Cancer**. Dec;150:123-131 (2020).
154. *Avelumab Maintenance for Urothelial Carcinoma*. **New England Journal of Medicine**. Dec 17;383(25):2482-2483 (2020).
155. *The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma*. **Expert Review of Anticancer Therapy**. Dec 23;1-12 (2020).
156. *The interplay between cholesterol (and other metabolic conditions) and immune checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient"*. **Human Vaccines & Immunotherapeutics**. Jan 10:1-5 (2021).
157. *Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis*. **Critical Reviews in Oncology/Hematology**. Feb 2:103241 (2021).
158. *The right immune-modulation at the right time: Thymosin α1 for prevention of severe Covid-19 in cancer patients.* **Future Oncology**. Mar;17(9):1097-1104 (2021).
159. *Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)*. **American Journal of Clinical Oncology**. Mar 1;44(3):121-125 (2021).
160. *Cytoreductive Nephrectomy in the Era of Targeted- and Immuno-Therapy for Metastatic Renal Cell Carcinoma: an Elusive Issue? A Systematic Review of the Literature.* **Critical Reviews in Oncology/Hematology**. Mar 2:103293 (2021).
161. *Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.* **European Journal of Cancer**. Mar 12;148:24-35 (2021).
162. *The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer*. **ESMO Open**. Mar 15;6(2):100078 (2021).
163. *Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials*. **Human Vaccines & Immunotherapeutics**. Apr 21;1-6 (2021).
164. *PD-L1 SNPs as biomarkers to define benefit in advanced NSCLC patients treated with immune checkpoint inhibitors.* **Tumori Journal**. May 18:3008916211014954 (2021).
165. *INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)*. **Journal for ImmunoTherapy of Cancer**. May;9(5):e002619 (2021).
166. *Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)*. **Therapeutic Advances in Medical Oncology**. May 18;13:17588359211019642 (2021).
167. *Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy*. **European Journal of Cancer**. Jun;150:224-231 (2021).
168. *Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O). A real-world study on behalf of Meet-URO group (MeetUro-7b)*. **Frontiers Oncology**. Jun 8;11:682449 (2021).
169. *PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort*. **Journal of Translational Medicine**. Jun 24;19(1):270 (2021).
170. *Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?* **Therapeutic Advances in Urology**. Jul 8;13:17562872211029784 (2021).
171. *Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)*. **Clinical Medicine Insights: Oncology**. Jul 8;15:11795549211021667 (2021).
172. *Pulmonary metastasectomy in renal cell carcinoma: predictive and prognostic elements from paired histopathological analysis of primary tumours and respective metastases*. **Journal of Onco-Nephrology**. Jul 13;5(2):96-104 (2021).
173. *Docetaxel and prednisone with or without enzalutamide as first line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial*. **European Journal of Cancer**. Aug 3;155:56-63 (2021).
174. *Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy*. **European Journal of Cancer**. Aug 12:S0959-8049(21)00459-7 (2021).
175. *Differential diagnosis of COVID-19 at the chest computed tomography scan: a review with special focus on cancer patients.* **World Journal of Radiology**. Aug 28;13(8):243-257 (2021).
176. *Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study*. **Clinical Medicine Insights: Oncology**. Sep 8;15:11795549211043427 (2021).
177. *Review on radiological evolution of COVID-19 pneumonia using computed tomography*. **World Journal of Radiology**. Sep 28;13(9):294-306 (2021).
178. *Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study*. **Targeted Oncology**. Sep;16(5):625-632 (2021).
179. *Transient asymptomatic pulmonary opacities (TAPO) and interstitial lung disease (ILD) in EGFR-mutated NSCLC treated with osimertinib*. **Tumori Journal**. Sep 29;3008916211047888 (2021).
180. *GU-CA-COVID: a clinical audit among Italian Genito-Urinary Oncologists during the first COVID-19 outbreak*. **Therapeutic Advances in Urology**. Oct 22;13:17562872211054302 (2021).
181. *Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature*. **Cancers**. Oct 28;13(21):5403 (2021).
182. *Is there a preferred first-line systemic treatment for metastatic renal cell carcinoma? A network meta-analysis*. **Therapeutic Advances in Urology**. Oct 29;13:17562872211053189 (2021).
183. *First-line Pazopanib in Patients with Advanced Non-Clear Cell Renal Carcinoma: an Italian Case Series*. **World Journal of Clinical Oncology**. Nov 24;12(11):1037-1046 (2021).
184. *Prognostic value of thyroid hormone ratio in patients with advanced metastatic renal cell carcinoma: results from the ThreeFour Study (Meet-URO 14)*. **Frontiers in Oncology**. Nov 25;11:787835 (2021).
185. *Chemotherapy, Target Therapy and Immunotherapy: Which Drugs Can Be Safely Used in The Solid Organ Transplant Recipients?* **Transplant International**. 2021 Dec;34(12):2442-2458 (2021).

186. *Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer A Multicenter International Cohort Study*. **JAMA Oncology**. Dec 1;7(12):1856-1861 (2021).
187. *Role of bone metastases in patients receiving immunotherapy for pre-treated urothelial carcinoma: the multicentre, retrospective Meet-URO-1 Bone study*. **Clinical Genitourinary Cancer**. Dec 16:S1558-7673(21)00238-X (2021).
188. *MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma*. **Journal of Clinical Pathology**. Jan 2022:75(1):39-44 (2022).
189. *Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).* **Expert Review of Anticancer Therapy**. Jan;22(1):115-121 (2022).
190. *High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.* **Journal of Hematology and Oncology**. Jan 21;15(1):9 (2022).
191. *Renal cell carcinoma and viral infections: a dangerous relationship?*. **World Journal of Nephrology**. Jan 22;11(1):1-12 (2022).
192. *Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)*. **Immunotherapy**. Feb;14(2):107-114 (2022).
193. *Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis*. **Immunotherapy**. Feb;14(2):145-153 (2022).
194. *Application of the Meet-URO score to metastatic renal cell carcinoma (mRCC) patients treated with second- and third-line cabozantinib*. **Therapeutic Advances in Medical Oncology**. Feb 26;14:17588359221079580 (2022).
195. *Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives*. **Cancers**. Feb 28;14(5):1245 (2022).
196. *Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES Study*. **European Urology**. Mar;81(3):274-282 (2022).
197. *Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?*. **Anticancer Research**. Mar;42(3):1487-1493 (2022).
198. *Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.* **Cancer Immunology, Immunotherapy**. Apr;71(4):865-874 (2022).
199. *Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study*. **Journal of Personalized Medicine**. Apr 30;12(5):727 (2022)
200. *Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?* **Urologic Oncology: Seminars and Original Investigations**. Apr 14:S1078-1439(22)00066-7 (2022).
201. *Cabozantinib as first line treatment in metastatic collecting ducts renal cell carcinoma: results of the BONSAI trial (Meet-URO 2 study)*. **JAMA Oncology**. Jun 1;8(6):910-913 (2022).
202. *Reassessing Human Adipose Tissue*. **New England Journal of Medicine**. Jun 2;386(22):e61 (2022).
203. *Statin use improves the efficacy of nivolumab in patients with advanced Renal Cell Carcinoma*. **European Journal of Cancer**. Jun 30;172:191-198 (2022).
204. *Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade*. **European Journal of Cancer**. Jun 30;172:199-208 (2022).
205. *First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin*. **Annals of Oncology** Aug 2:S0923-7534(22)01862-2 (2022).
206. *Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors*. **Frontiers in Oncology**. Aug 16;12:918413 (2022).
207. *Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: the Meet-Uro 19 BEYOND study*. **Cancer Medicine**. Aug 19;11(16):3048-3056 (2022).
208. *Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies*. **Targeted Oncology** Sep;17(5):571-581(2022).
209. *The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: the Δ-Meet-URO analysis*. **Frontiers in Oncology**. Sep 23;12:955501 (2022).
210. *The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study*. **Journal of Translational Medicine**. Sep 30;20(1):435 (2022).
211. *Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma*. **Biomedicines**. Sep 30;10(10):2444 (2022).
212. *The geriatric G8 score predicts survival outcomes in older patients with advanced prostate cancer in the ADHERE prospective study of the Meet-URO network*. **Current Oncology**. Oct 14;29(10):7745-7753 (2022).
213. *What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?* **Journal of Thoracic Oncology**. Oct;17(10):e89-e90 (2022).
214. *Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib*. **Immunotherapy**. Nov;14(16):1297-1305 (2022).
215. *Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.* **ESMO Open**. Dec 6;7(6):100634 (2022).
216. *Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report*. **Immunotherapy**. Dec;14(18):1419-1427 (2022).
217. *Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario*. **Journal for Technology in Cancer Research & Treatment**. Jan-Dec;22:15330338231159753 (2023).
218. *Concomitant Drugs Prognostic Score in Patients with Metastatic Renal Cell Carcinoma receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication*. **Journal of Immunotherapy**. Jan 1;46(1):22-26 (2023).
219. *The impact of proton pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma*. **Anticancer Drugs**. Jan 1;34(1):178-186 (2023).
220. *Exploring Genetic and Immune Underpinnings of the Sexual Dimorphism in Tumor Response to Immune Checkpoints Inhibitors: A Narrative Review*. **Journal for Current Research in Pharmacology and Drug Discovery**. Jan;4:100146 (2023).
221. *Cabozantinib in advanced renal cell carcinoma patients pre-treated with ICIs: the phase 2 BREAKPOINT trial (Meet-Uro trial 03)*. **Tumori Journal**. Feb;109(1):129-137 (2023).

222. *Pembrolizumab plus axitinib for metastatic papillary and chromophobe renal cell carcinoma. NEMESIA (Non clEar MEtaStatic renal cell carcinoma pembrolIzumab Axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)*. **International Journal of Molecular Sciences**. 24(2):1096 (2023).
223. *Role of clock genes and circadian rhythm in renal cell carcinoma: recent evidence and therapeutic consequences*. **Cancers**. 15(2):408 (2023).
224. *The role of CT imaging in characterization of small renal masses*. **Diagnostics**. 13(3):334 (2023).
225. *Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): results from a double-blind, randomised, phase 3 trial*. **The Lancet**. Mar 11;401(10379):821-832 (2023).
226. *Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study*. **Cancers**. Apr 21;15(8):2394 (2023).
227. *Tailoring the treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?* **Expert Review of Anticancer Therapy**. May;23(5):545-554 (2023).
228. *A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA score*. **Minerva Urology and Nephrology**. Jun;75(3):308-318 (2023).
229. *The Role of the Caregiver in Older Patients with Advanced Prostate Cancer: Results from the ADHERE Prospective Study of the Meet-URO Network*. **Supportive Care in Cancer**. Jun 26;31(7):425 (2023).
230. *Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study*. **eClinicalMedicine**. Jun 29;61:102044 (2023).
231. *The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors*. **Cancer Immunology, Immunotherapy**. Jul;72(7):2127-2135 (2023).
232. *A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study*. **Critical Reviews in Oncology/Hematology**. Jul;187:104016 (2023).
233. *Global real-world outcomes of patients receiving immuno-oncology combinations for advanced Renal Cell Carcinoma: the ARON-1 study*. **Targeted Oncology**. Jul;18(4):559-570 (2023).
234. *Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer*. **Clinical Cancer Research**. Jul 14;29(14):2714-2724 (2023).
235. *The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study*. **Therapeutic Advances in Urology**. Jul 22;15:17562872231187216 (2023).
236. *Integrating red blood cell features and hemoglobin levels in metastatic renal cell carcinoma patients treated with pazopanib or cabozantinib: an easily exploitable prognostic score*. **Frontiers in Bioscience-Elite**. Jul 28;15(3):20 (2023).
237. *BONSAI-2 study: nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma (mCDC) patients*. **Tumori Journal**. Aug;109(4):418-423 (2023).
238. *Prognostic models for patients with metastatic urothelial carcinoma: why to use them?* **Minerva Urology and Nephrology**. Aug;75(4):419-421 (2023).
239. *Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab*. **Immunotherapy**. Aug;15(11):827-837 (2023).
240. *Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations*. **Minerva Urology and Nephrology**. Aug;75(4):460-470 (2023).
241. *Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity*. **Exploration of Targeted Anti-tumor Therapy**. Aug 31;4:743-756 (2023).
242. *Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial*. **Targeted Oncology**. Sep;18(5):639-641 (2023).
243. *Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced Urothelial Carcinoma: the ARON-2 study*. **Cancer Immunology, Immunotherapy**. Sep;72(9):2961-2970 (2023).
244. *Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors.* **BMJ Supportive & Palliative Care**. Sep 4;spcare-2023-004558 (2023).
245. *Percutaneous Ablation of T1 Renal Masses: Comparative Local Control and Complications After Radiofrequency and Cryoablation.* **Diagnostics**. Sep 26;13(19):3059 (2023).
246. *Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)*. **Clinical Genitourinary Cancer**. Oct;21(5):e309-e319.e1 (2023).
247. *Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer*. **Journal of Oncology Pharmacy Practice**. Oct;29(7):1748-1753 (2023).
248. *Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival*. **Cancers**. Oct 19;15(20):5052 (2023).
249. *Use of concomitant proton pump inhibitors, statins, or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: Data from the ARON-2 retrospective study*. **Cancer Immunology, Immunotherapy**. Nov;72(11):3665-3682 (2023).
250. *Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study*. **Cancer Immunology, Immunotherapy**. Nov;72(11):3707-3716 (2023).
251. *Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts*. **Current Oncology Reports**. Nov;25(11):1345-1362 (2023).
252. *Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab*. **JAMA Network Open**. Nov 1;6(11):e2345185 (2023).
253. *Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.* **iScience**. Nov 17;26(11):107970 (2023).
254. *Wolf in sheep's clothing or not? The pT1 LG dilemma.* **Minerva Urology and Nephrology**. Dec;75(6):773-775 (2023).

255. *Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors*. **Journal of the National Cancer Institute**. Dec 6;115(12):1605-1615 (2023).
256. *Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies*. **British Journal of Cancer**. Jan;130(1):135-142 (2024).
257. *Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice?*. **Future Oncology**. Jan;20(3):107-111 (2024).
258. *Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate*. **Cancer Medicine**. Jan 2;13(1):e6853 (2024).
259. *Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?*. **European Urology Oncology**. Feb;7(1):102-111 (2024).
260. *Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study*. **Frontiers in Oncology**. Feb 12;14:1307635 (2024).
261. *Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study*. **Scientific Reports**. Feb 28;14(1):4949 (2024).
262. *Prognostic impact of blood lipid profile in patients with advanced solid tumors treated with immune checkpoint inhibitors: a multicenter cohort study*. **The Oncologist**. Mar 4;29(3):e372-e381 (2024).
263. *Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis*. JAMA Network Open. Mar 4;7(3):e241215 (2024).
264. *Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: A comprehensive pan-cancer analysis*. **Journal for ImmunoTherapy of Cancer**. Mar 7;12(3):e008806 (2024).
265. *Treatment of metastatic TFE3 microphthalmia transcription factor translocation renal cell carcinoma: a case report*. **Translational Pediatrics**. Mar 22;13(3):499-507 (2024).
266. *Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study*. **European Urology**. Mar 22:S0302-2838(24)02132-8 (2024).
267. *Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)*. **Clinical Genitourinary Cancer**. Apr;22(2):126-133.e2 (2024).
268. *Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib*. **Clinical Genitourinary Cancer**. Apr;22(2):514-522.e1 (2024).
269. *Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis*. **European Urology Oncology**. Apr;7(2):179-188 (2024).
270. *External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations.* **Clinical & Experimental Metastasis**. Apr;41(2):117-129 (2024).
271. *Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients*. **Therapeutic Advances in Urology**. Apr 17:16:17562872241244574 (2024).
272. *Global real-world experiences with Pembrolizumab in Advanced Urothelial Carcinoma after platinum-based chemotherapy: the ARON-2 study*. **Cancer Immunology, Immunotherapy**. Apr 18;73(6):106 (2024).
273. *Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study*. **Clinical Genitourinary Cancer**. Jun;22(3):102074 (2024).
274. *Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27*. **Clinical Genitourinary Cancer**. Jun;22(3):102078 (2024).
275. *Analyses of tumor microenvironment in advanced renal cell carcinoma patients receiving immunotherapy (Meet-URO 18 study)*. **Future Oncology**. Jun;20(21):1495-1503 (2024).
276. *Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations*. **Cancer Immunology, Immunotherapy**. Jun 4;73(8):142 (2024).
277. *International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study)*. **BMC Cancer**. Jun 24;24(1):757 (2024).
278. *Pembrolizumab plus enfortumab vedotin in urothelial cancer*. **Nature Reviews Urology**. Jul;21(7):387-388 (2024).
279. *Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma*. **European Journal of Cancer**. Jul:205:114097 (2024).
280. *Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies*. **ESMO Open**. Jul;9(7):103484 (2024).
281. *Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study*. **Cancer Immunology, Immunotherapy**. Jul 2;73(9):161 (2024).
282. *Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study*. **Frontiers in Immunology**. Jul 5:15:1361010 (2024).
283. *Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy*. **Immunotherapy**. 16(13):859-868 (2024).
284. *A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study*. **Immunotherapy**. 16(14-15):963-973 (2024).
285. *Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments*. **Biochemical Pharmacology**. Aug:226:116397 (2024).
286. *Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study*. **Cancer Letters**. Aug 1:596:217001 (2024).
287. *Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab*. **Immunotherapy**. Aug 19;16(18-19):1095-1103 (2024).
288. *Comparing a Part with the Whole: Beware of the Disparity of the Renal Cell Carcinoma Prognostic Models*. **Annals of Surgical Oncology**. Sep;31(9):5865-5866 (2024).

289. *Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project*. **Targeted Oncology**. Sep;19(5):747-755 (2024).
290. *READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma*. **ESMO Real World Data and Digital Oncology**. Sep 5;5(C):100068 (2024).
291. *Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study*. **European Urology Oncology**. Oct;7(5):1123-1131 (2024).
292. *Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)*. **Targeted Oncology**. Oct;7(5):1123-1131 (2024).
293. *Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project*. **Clinical & Experimental Metastasis**. Oct;41(5):655-665 (2024).
294. *Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney.* **Clinical Genitourinary Cancer**. Oct;22(5):102186 (2024).
295. *Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy*. **Cancer Immunology, Immunotherapy**. Oct 3;73(12):246 (2024).
296. *Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)*. **Targeted Oncology**. Nov;19(6):893-903 (2024).
297. *Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2^{EV} Study*. **Targeted Oncology**. Nov;19(6):905-915 (2024).
298. *Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study*. **Bladder**. Nov 27;11(4):e21200019 (2024).
299. *Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors*. **Journal of Immunotherapy**. Nov-Dec;47(9):388-394 (2024).
300. *First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study*. **European Urology**. Dec;86(6):503-512 (2024).
301. *Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)*. **International Journal of Cancer**. Dec 1;155(11):2036-2046 (2024).
302. *Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau"*. **Human Vaccines & Immunotherapeutics**. Dec 31;20(1):2351669 (2024).
303. *Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study*. **Clinical Genitourinary Cancer**. Feb;23(1):102267 (2025).
304. *Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns of acquired resistance to immunotherapy in patients with NSCLC*. **Clinical Cancer Research**. In press 2024.
305. *The effect of concomitant drugs on oncological outcomes in patients treated with Immune Checkpoint Inhibitors for metastatic Urothelial Carcinoma: a narrative review*. **Oncology Research**. In press 2024.
306. *First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study*. **Cancer Immunology, Immunotherapy**. In press 2024.
307. *Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study*. **European Urology Oncology**. In press 2024.
308. *Real-life impact of enfortumab vedotin or chemotherapy in the sequential treatment of advanced urothelial carcinoma: the ARON-2 retrospective experience*. **Cancer Medicine**. In press 2024.

Lingue Straniere:

Conoscenza buona della lingua inglese scritta e scolastica di quella parlata.

UNIVERSITÀ DI PARMA
Firmato digitalmente da Sebastiano Buti
Data: 11.02.2025 10:03:15 CET

Informatica:

Ottima conoscenza dei programmi più diffusi per PC (Word, Excel, Power Point) e discreta conoscenza dei programmi di statistica SPSS e JAMOVI.

CONTATTI

@ E-mail

sebastiano.buti@unipr.it (mailto:sebastiano.buti@unipr.it)

Ubicazione dell'ufficio

Dipartimento di Medicina e Chirurgia dell'Università di Parma
U.O. Oncologia, Padiglione 15 "Cattani", Piano Rialzato - Azienda Ospedaliero-Universitaria di Parma
Viale Gramsci n. 14, 43126 - Parma, Italia.